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Abstract The pathophysiologies of neurodegenerative dis-
eases, including amyotrophic lateral sclerosis (ALS),
Parkinson’s disease (PD), and Alzheimer’s disease (AD), are
far from being fully explained. Oxidative stress (OS) has been
proposed as one factor that plays a potential role in the path-
ogenesis of neurodegenerative disorders. Clinical and preclin-
ical studies indicate that neurodegenerative diseases are char-
acterized by higher levels of OS biomarkers and by lower
levels of antioxidant defense biomarkers in the brain and pe-
ripheral tissues. In this article, we review the current knowl-
edge regarding the involvement of OS in neurodegenerative
diseases, based on clinical trials and animal studies. In addi-
tion, we analyze the effects of the drug-induced modulation of
oxidative balance, and we explore pharmacotherapeutic strat-
egies for OS reduction.
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Introduction
Identifying factors that contribute to neurodegenerative pro-
cesses in the brain is one of the major goals of modern med-
icine. Currently, there are several hypotheses concerning the
mechanisms that lead to the damage and death of brain cells in
neurodegenerative diseases, such as excitotoxic effects by ex-
citatory amino acids, disturbed cellular energy metabolism,
and oxidative stress (OS), which is caused by free radicals or
other reactive molecules.
The excessive production of reactive species and insuffi-
cient activity of antioxidant defense mechanisms have been
implicated in the pathogenesis of many neurodegenerative
diseases, including amyotrophic lateral sclerosis (ALS),
Parkinson’s disease (PD), Alzheimer’s disease (AD), and
Huntington disease (HD) [1].
Reactive Species, Sources, and Cellular
Pro-/Antioxidant Balance
It is thought that the biological oxidants that cause oxidative
damage comprise the products of endogenous and exogenous
processes that involve oxygen and nitrogen. Reactive species
that contain oxygen are produced during aerobic respiration,
cellular metabolism, and defense against pathogens [2]. The
chemical potential of the oxygen molecule relies on its
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electron structure (two unpaired electrons in its basic triplet
state). It promotes one-electron reactions that form the basis
for respiration (reduction of oxygen molecules in four single-
electron reactions), microsomal electron transport chains
(ETC) (via cytochrome P-450 (CYP 450)), and oxidative
burst activity in macrophages [3].
The high dynamics of the chemical processes that are
achieved in elementary single-electron reactions are desirable
and are the source of reactive molecules, which are either
undesirable side products (respiration and metabolism) or in
excess of the established requirements (defense process). The-
se reactive molecules are known as reactive oxygen species
(ROS) and reactive nitrogen species (RNS). Among them, the
best known are singlet oxygen (1O2), superoxide anion radi-
cals (O2
−•), hydroxyl radicals (HO•), hydrogen peroxide
(H2O2), nitric oxide (NO), and peroxynitrite anions (ONOO
−)
[4, 5].
At physiological concentrations, ROS/RNS play important
regulatory and mediator functions, but an uncontrolled in-
crease in ROS/RNS concentrations leads to a chain of radical
reactions that increases the risk of damage to biological mol-
ecules in a living organism. This is caused by the high reac-
tivity of ROS and RNS with lipids, proteins, carbohydrates,
and nucleic acids. Hence, establishing an antioxidant barrier is
required to limit the amount of ROS/RNS to a level that is not
threatening to the integrity of biological systems. Excessive
formation of ROS/RNS that exceeds the maximum capacity
of the antioxidant barrier leads to a disturbance in the pro-/
antioxidant equilibrium and, finally, to the development of the
state known as OS.
OS can be triggered by radicals produced by either exoge-
nous processes (e.g., xenobiotics, cold, viral and bacterial in-
fections, ionizing radiation, ultrasound or photo-oxidation,
poor diet, alcohol consumption, and smoking) or endogenous
processes, which are the basic biochemical reactions in the
body mentioned earlier (Fig. 1).
ROS production as a side effect of aerobic respiration oc-
curs on the inner membrane of the mitochondrion [6] (Fig. 2).
The respiratory chain (mitochondrial ETC) consists of a series
of membrane-bound complexes, such as complex I (reduced
form of nicotinamide adenine dinucleotide (NADH)/ubiqui-
none reductase), complex II (succinate ubiquinone reductase),
complex III (ubiquinol cytochrome c reductase), complex IV
(cytochrome c oxidase), and complex V (adenosine triphos-
phate (ATP) synthase) [7]. The final acceptor of electrons and
protons, an oxygen molecule, undergoes four-electron reduc-
tion, which can lead to the production of water molecules.
During ETC, single electrons leak to reducemolecular oxygen
and to form O2
−• and, later, H2O2 and HO
• [8] (Fig. 1).
Because of its high consumption of oxygen and its high
lipid content, the brain is particularly vulnerable to damage
caused by ROS and RNS. The extent of the damage varies,
depending on, among other factors, the source and type of the
reactive species. More active molecules, such as HO• and
ONOO−, interfere with other molecules at the site of their
production, while less active ones, such as 1O2 and O2
−•, can
diffuse over longer distances and produce effects in more spe-
cific locations [9]. They can also react with each other and
form more active forms, as in the case of the reaction of O2
−•
with NO, which creates ONOO− [10].
In mitochondria, NO is produced from L-arginine and L-
citrulline in a reaction that is catalyzed by nitric oxide synthase
(NOS), which has three isoforms with different tissue locali-
zations. Cellular Ca2+-dependent neuronal NOS (nNOS) is
expressed in astrocytes, microglia, and macrophages, and en-
dothelial NOS (eNOS) is expressed in the vascular endotheli-
um and Ca2+-independent inducible NOS (iNOS). NO is in-
volved in many important processes within the central ner-
vous system, such as the regulation of cerebral blood flow
and memory. In addition, it plays a significant role in the
regulation of the immune system, including the modulation
of cytokine production. The released NO acts on neighboring
cells, leading to somatic mutations and affecting cell cycle
regulatory proteins, apoptosis, and DNA repair [11].
RNS are important for the generation of OS. ONOO− is
rapidly decomposed into HO•, nitrogen dioxide radical
(NO2
•), and nitryl cation (NO2
+). All of these can damage
nerve cells [12].
These highly reactive compounds induce changes in the
structure and function of cell membranes, proteins, lipopro-
teins, enzymes, hormones, and genetic material. In particular,
membranes are a primary target for ROS. Conversion prod-
ucts of lipid peroxidation lead to the decomposition of poly-
unsaturated fatty acids and the formation of the final products,
i.e., the reactive aldehydes, such as malondialdehyde (MDA)
and 4-hydroxynonenal (HNE). These compounds react with
DNA or protein molecules and modify their structure and
functions [13, 14].
There are several mechanisms designed to protect the
organism from the harmful effects of ROS and RNS. The
ultimate amount of ROS/RNS is under strict control in the
body as a result of enzymatic and non-enzymatic defense
mechanisms. The production of ROS- and RNS-induced
damage (the final effect of OS) in tissue can be confirmed
by the presence of tissue-specific and non-specific bio-
markers [15–20]. Several markers of OS and antioxidant
activity are presented in Fig. 2. Recent technical advances
used to detect and identify ROS/RNS biomarkers and free
radical metabolism are electron spin resonance (ESR), the
immuno-spin trapping technique (IST), and radioimmuno-
assay (RIA) [21, 22].
The cellular antioxidant system, designed to prevent dam-
age to tissue, is composed of antioxidant enzymes and other
non-enzymatic compounds that have the ability to reduce dif-
ferent chemical structures [21]. These compounds are respon-
sible for maintaining the balance between pro- and antioxidant
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agents and alleviating OS (see Table 1). The essential compo-
nents of the enzymatic antioxidant defense are superoxide
dismutase (SOD), catalase (CAT), glutathione peroxidase
(GPx), and glutathione reductase (GR), while the non-
enzymatic antioxidants include glutathione (GSH),
thioredoxin (Trx), vitamins A, E, and C, flavonoids, trace
elements, and proteins, e.g., albumin, ceruloplasmin, and
metallothionein.
A large body of evidence confirms a relationship between
OS and the development of neurodegenerative diseases. The
increased neuronal ROS production and accumulation of ox-
idative damage that occurs with age correlate well with the
extent of neurodegeneration. In the following sections of this
article, we present the current knowledge on the relationships
between the intensity of OS and the initiation and progression
of the major neurodegenerative diseases AD, PD, and ALS.
The assessment of these relationships is based on biomarkers
of OS and indicators of the pro-/antioxidant balance in ner-
vous tissue that are correlated with the typical characteristics
of neurodegenerative processes.
Amyotrophic lateral sclerosis (ICD-10 G12.21)
ALS (also known also as Charcot’s or Lou Gehrig’s disease) is
a severe neurodegenerative disease that is characterized by
progressive upper motor neuron loss in the cerebral cortex
and lower motor neuron loss in the brainstem and spinal cord
[23, 24]. This results in spasticity, muscle wasting, and weak-
ness, leading finally to paralysis and difficulties with speech,
swallowing, and breathing. ALS may have either a limb onset
(80 % cases) or a bulbar onset (20 % cases) [24, 25]. There is
currently no cure for ALS and only riluzole, which acts on
glutamate signaling, has been registered for the treatment of
the disease. Riluzole was shown to slow disease progression
and to improve limb function; however, the survival of pa-
tients was prolonged by only 2–3 months and death due to
respiratory failure occurred in most cases within 3–5 years of
the diagnosis [26].
The main pathological hallmark of ALS is the formation of
cytoplasmic aggregates in degenerating motor neurons and
surrounding oligodendrocytes, but those inclusions are also
present in the frontal and temporal cortices, hippocampus,
and cerebellum [27].
Only 5–10 % of ALS cases are inherited (familial ALS
(FALS)); the remaining cases have no clear genetic back-
ground (sporadic ALS (SALS)) [24], and their pathogenesis
is still poorly understood. Studies concerning the mechanisms
of ALS development indicate that many factors, including
excitotoxicity, mitochondrial dysfunction, endoplasmic retic-
ulum stress, neuroinflammation, and OS, can be involved in
this process. The two forms of the disease are clinically indis-
tinguishable because the symptoms and pathological changes
in SALS and FALS are similar. FALS is caused by mutations
in some genes, such as those coding for SOD1, FUS RNA
binding protein, TAR DNA binding protein, vesicle-
associated membrane protein B, valosin-containing protein,
optineurin, alsin, senataxin, spatascin, angiogenin, or
ubiquilin-2 [24, 26]. Some of these gene mutations have also
been found in SALS patients [28, 29].
The most common known genetic mutation for ALS is the
recently described expandedGGGGCC hexanucleotide repeat
in the non-coding region of the C9Orf72 gene, on
Fig. 1 Generation of reactive
species (based on [280–283])
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chromosome 9p21 [30]. Another common mutation is local-
ized in SOD1. SOD1 in its native state metabolizes O2
−• to
molecular misfolding [31]. Pathogenic mutations of SOD1
enzyme can be present in different regions of the enzyme,
e.g., G93A (glycine 93 changed to alanine), H46R (histidine
at codon 46 changed to arginine), or A4V (alanine at codon 4
changed to valine). Mutated SOD1 can form cytotoxic protein
aggregates alone or with other proteins what possibly leads to
loss of the enzymatic function or to acquiring the toxic prop-
erties [32, 33]. As SOD1 plays a crucial role in O2
−• clearance,
its functional loss can lead to increased levels of OS. Then, the
remaining wild-type SOD1 may become itself a target of ox-
idative modification after which it dissociates from dimers to
monomers and further forms aggregates with toxic properties
of mutant forms of SOD1. That was shown in in vitro studies
[34, 35]. Accumulation of abnormal SOD1 was also con-
firmed in the spinal cord [34] in animal studies [36, 37] as
well as in ALS patients [38].
Clinical Studies
OS Biomarkers
Post-mortem studies on tissue samples from SALS and
FALS patients support the hypothesis of oxidative damage
of proteins, lipids, and DNA. For instance, HNE and 3-
nitrotyrosine (3-NT) levels were increased in CSF in
SALS patients [39, 40], while a rise in 8-hydroxy-2′-
deoxyguanosine (8-OHdG) has been described in both
Fig. 2 Source of radical and OS biomarkers. 8-OHA 2,8-
hydroxyadenine, HNE 4-hydroxynonenal, 5-OHC 5-hydroxycytosine,
5-OHU 5-hydroxyuracil, 8-OHdG 8-hydroxy-2′-deoxyguanosine, 8-
OH-Gua 8-hydroxyguanine, AGEs advanced glycation end products,
ALES advanced lipid peroxidation end products, AOPP advanced
oxidation products, CTL creatol, COX cyclooxygenases, CYP
cytochrome P450, ETC electron transport chain, F2-isoPs F2-
i s o p r o s t a n e s , F 4 - N P s F 4 - n e u r o p r o s t a n e s , HE T E
hydroxyeicosatetraenoic acids, HODE hydroxyoctadecadienoic acid,
HIF-1a hypoxia-inducible factor-1a, IsoF isofuran, LF lipofuscin, LOX
l ipoxygenases, Lyso PC lysophosphat idylchol ines, MPO
myeloperoxidase, NOX NADPH oxidases, NFS neurofuran, Opht A
ophthalmic acid, GSSG oxidized glutathione, ox-LDL oxidized LDL,
GSSG/GSH oxidized/reduced glutathione, Prxs peroxiredoxins, PC
protein carbonyl, TBARS thiobarbituric acid reactive substances, TQ/
TQH2 tocopherylquinone/tocopheryl hydroquinone, TAC total
antioxidant capacity, Tyr tyrosines, UQ/UQH2 ubiquinone/ubiquinol,
XO xanthine oxidase
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SALS and FALS patients [41, 42]. However, no correla-
tion between these markers and the severity or duration of
the disease has been found [43].
Raised levels of thiobarbituric acid reactive substances
(TBARS) and advanced oxidation protein products (AOPP)
and decreased ferric-reducing ability of plasma (FRAP) were
detected in the plasma or erythrocytes of SALS patients
[44–46], but plasma protein carbonyl (PC) levels surprisingly
did not differ between SALS patients and control subjects
[16]. More conclusive results came from a study where urine
from SALS patients contained a higher level of isoprostanoids
(IsoPs) and 8-OHdG compared to a control group [16, 47],
suggesting that IsoPs and 8-OHdG could be considered
markers of OS in ALS. These studies included only 50
Table 1 Enzymatic and non-enzymatic antioxidants against OS
Agents Mechanism
Enzymatic
Superoxide dismutases (SOD)
CuZn-SOD, located in the cytoplasm
Mn-SOD, located in the mitochondria
EC-SOD extracellular
Scavenges superoxide anion to form H2O2
Catalases (CATs) Peroxisomes remove the hydrogen peroxide
Peroxiredoxins (Prxs) Reduce free hydrogen peroxide to water
Glutathione peroxidases (GPx) Catalyzes the reduction of H2O2 and alkyl hydroperoxides to H2O
Glutathione reductases (GRs) Catalyzes the reduction of oxidized glutathione (GSSG) to reduced glutathione (GSH)
Glutathione S-transferases (GSTs) Catalyze the conjugation of xenobiotics and endogenous or exogenous electrophilic
compounds to reduced glutathione
Thioredoxin reductases (TrxRs) Repair oxidative damages of proteins
Heme oxygenase-1 (HO-1) Creation of products with antioxidant properties
Metalloproteins
Metallothionein (MT) Physiological metal chelation (Zn, Cu, Se) and xenobiotic metals (Cd, Hg, Ag, As)
Albumin Chelation of metal ions (Fe, Cu)
Ceruloplasmin (CP) Chelation of metal ions (Cu)
Ferritin Chelation of metal ions (Fe)
Transferrin Chelation of metal ions (Fe)
Non-enzymatic
Vitamin C (ascorbic acid) ROS scavenger
Vitamin E (α-tocopherol) ROS scavenger
Vitamin A (retinol) ROS scavenger
Carotenoids ROS scavenger
Melatonin ROS scavenger
Reduced nicotinamide adenine dinucleotide phosphate
(NADPH)
Coenzyme used in anabolic reactions
Adenosine (ADO) Endogenous activator of the cellular antioxidant defense system
Uric acid ROS scavenger
Ubiquinol (the reduced form of coenzyme Q-10) ROS scavenger
Polyphenols ROS scavenger, metal chelation, induction of antioxidant enzymes
Phenolic acids
Flavonoids
Stilbenes
GSH reduced glutathione ROS scavenger
Amino acids (cysteine, homocysteine, methionine, taurine) ROS scavenger
α-Lipoic acid ROS scavenger
Lycopene ROS scavenger
Carotenoids ROS scavenger
S-adenosyl-L -methionine ROS scavenger
Selenium ROS scavenger
Data from [274–279]
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participants with SALS compared to 46 control subjects.
Thus, these results should be confirmed in larger cohorts.
The presence of OS biomarkers in regions of the CNS that
are critical for ALS suggests that they are implicated in motor
neuron degeneration. This fact is supported by very recent
positron emission tomography (PET) imaging data in humans,
which confirmed that OS were enhanced in the motor cortex
in ALS patients compared with controls. Moreover, the ob-
served OS increase in the mild stage of the disease led to the
conclusion that OSmay be an important factor associated with
the development of neurodegeneration in ALS patients [48].
Antioxidant Defense Biomarkers
Most studies concerning antioxidant defense biomarkers in
ALS patients have shown changes in peripheral tissues or in
CSF but rarely in the brain. For example, GSH levels were
reduced in erythrocytes in ALS patients [45]. In contrast, an
earlier study demonstrated a lower GSSG/GSH ratio with a
concomitant rise in NO in the CSF of SALS patients [49].
According to the latter study, the lower GSSG/GSH level
was caused by the decreased production of O2
−•-oxidizing
GSH because of the shift of oxidation to NO production or
oxidation [49]. Very recent in vivo imaging studies have
shown decreased GSH levels in the motor cortex of ALS
patients by using the J-editing technique or 62copper-
diacetyl-bis(N4-methylthiosemicarbazone (62CU-ATSM))
PET technique [25, 48].
The activity of SOD decreased in red blood cells and the
CSF of FALS- and SALS-diagnosed patients [42, 50–52].
Interestingly, the reduction in the SOD1 protein concentration
in erythrocytes of FALS patients correlated with SOD1 gene
mutations [42]. However, SALS patients displayed enhanced
activity of SOD1 in CSF [53], indicating that this different
outcome may depend on either the ALS type, the disease
duration, or the sampling time [54].
Apart from SOD, the activity of CAT, another antioxidant
defense enzyme, was also found to be diminished in red blood
cells in FALS [51] and SALS [51, 52] patients. Another study
revealed that CAT activity decreased in erythrocytes with dis-
ease progression, which may suggest a link between this pa-
rameter and ALS duration [45].
Results regarding GPx or GR activity in ALS patients are
controversial. GPx type 3 (also known as plasma GPx) and
GR levels were lower in the serum or in red blood cells,
respectively, in ALS patients [45, 55]. In contrast, another
study showed enhanced GPx in the serum and CSF of ALS
patients [56], while GR activity was elevated in the erythro-
cytes in both SALS and FALS patients [51, 52]. One study
reported no change in GR activity in red blood cells in SALS
patients [57].
In ALS patients, the plasma and/or CSF levels of other
antioxidants (i.e., vitamin E, β-carotene, vitamin C, uric acid,
and thiol group-containing molecules, such as ubiquinol-10)
were either elevated [53] or not changed [44, 58, 59].
These divergent results could be explained by the het-
erogeneity of ALS [60]. In fact, ALS-diagnosed patients
vary in their rate of disease progression and may differ in
the number of years of survival. The median survival
from onset to death in ALS varies from 20 to 48 months;
however, many studies have reported a survival time of
longer than 10 years in 10–20 % of patients [60]. More-
over, a study from Cova et al. [57] showed that the activ-
ity of GPx, GR, and CuZn SOD in erythrocytes was de-
creased in patients who had a faster disease progression
rate and that SOD1 activity significantly decreased along
the disease course in subjects with a more impaired func-
tional status. All of these results support the hypothesis
that ALS has many variants or mimic syndromes that
differ in their pathogenic mechanisms and in their profile
of enzymatic and non-enzymatic antioxidant responses
[57].
Pharmacological Strategies to Reduce OS
Several pharmacotherapeutic agents with antioxidant proper-
ties have been attempted to slow ALS progression; however,
most of them failed to do so (Table 2). Vitamin E, when com-
bined with riluzole, diminished TBARS levels, enhanced GPx
activity in the plasma, and prolonged the milder stages of the
ALSHealth State scale, but it did not affect survival andmotor
function [61].
Another study investigated a very high dose of vitamin E as
an add-on therapy to riluzole for ALS treatment; however, this
treatment with vitamin E, at a dose of 5,000 mg/day for
18 months, failed to slow disease progression [62]. On the
other hand, another study showed that intake of a combination
of polyunsaturated fatty acids and vitamin E reduced the risk
of developing ALS [63].
Edavarone (MCI-186) is another free radical scavenger that
is already approved to treat cerebral infarction and to investi-
gate ALS. It eliminates lipid peroxide and hydroxyl radicals
by transferring an electron to the radical and thereby exerting a
protective effect on neurons. In ALS patients, edavarone was
shown to diminish nitrosative stress (NS) in CSF [64] and is
now being tested in a phase III clinical trial in Japan for ALS
treatment [65]. CoenzymeQ10was administered for 9 months
in a dose of 2,700mg/day to ALS patients in a multicenter trial
that unfortunately showed a lack of compound efficacy for
ALS treatment [66]. This study also determined 8-OHdG
levels in the plasma; however, according to the authors, the
results for this measure will only be available later [66].
Other antioxidant medications, i.e., acetylcysteine, crea-
tine, or selegiline, had no significant effect on survival or the
rate of clinical progression of ALS [67–69]. In these studies,
the influence on antioxidant defense biomarkers and oxidant
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damage was not evaluated. In another study, melatonin was
used as a potential neuroprotective compound and, when nor-
malized to control values, was found to elevate the level of PC
in the serum of 31 SALS patients [70].
The novel antioxidant AEOL 10150, which is a small mol-
ecule that catalytically consumes ROS and RNS, is considered
to be the most promising compound under evaluation in a
clinical trial [71]. In a small, open-label study in ALS patients,
AEOL 10150 was shown to be a safe and well-tolerated drug
[71]. However, neither efficacy nor measurement of oxidative
biomarkers in ALS patients who were on AEOL 10150 has
been published.
The antioxidant medications used in ALS clinical trials
have so far been unable to slow the progression of the disease.
Moreover, a limited number of clinical studies have investi-
gated oxidative damage or changes in the antioxidant defense
status after antioxidant therapy.
Anti-ALS Drugs that Modulate the Oxidative Balance
No data.
Animal Studies
OS Biomarkers
The most popular animal models of ALS are based on SOD1
mutant transgenic mice (for example: SOD1 G93A, SOD1
H46R, SOD1H46R/H48Q, SOD1A4V, etc. (for more details,
see [72])). Other ALS models include Wobbler mice and ro-
dent models with genetic mutations in TAR DNA binding
protein of 43 kDa (TDP-43), VAMP-associated protein B,
dynactin or FUS/TLS, or C9Orf72 [73].
Changes in oxidative biomarkers have been detected in
ALS models in rodents (Table 3). For example, free radical
levels were elevated in the spinal cord of SOD1 G93A mice
post-mortem [74, 75], and trapped radical adducts were also
recently detected in the spinal cord of these mice in vivo [76].
In line with this latter observation, increased levels of PC in
the spinal cord and in the motor cortex [77, 78], MDA and 4-
HDA in the brain and CSF [79], and HNE, HNE-adducts, and
8-OHdG in the spinal cord [80, 81] have been observed in
several ALS animal models (see Table 3).
It has been established that enhanced nitration processes
are also present in animal models of ALS. For example, 3-
NT was found in the spinal cords of aged SOD1 G93A
mice together with the presence of overnitrated proteins
(actin or ATPase) in the spinal cord [82], in the motor
and sensory cortices [78], and in the peripheral blood
mononuclear cells [83] in transgenic mouse models of
ALS and that these were observed even before the onset
of the disease.
OS and NS are widely present in ALS, and in vitro studies
suggest that this mechanism can facilitate the formation of
protein aggregates [84]. In support of this conclusion, recent
studies have revealed that a selective nNOS inhibitor in-
creased survival in SOD1 transgenic mice [85].
Antioxidant Defense Biomarkers
In general, transgenic mouse models overexpressing mutant
human SOD1 showed increased activity by the enzyme [32].
However, in the end stage of the disease, SOD1 activity in
SOD1 G93A mice remained at the same level as wild-type
SOD in non-transgenic mice [86]. What is interesting is that
SOD1 knockout mice did not show an ALS-like phenotype
[32].
Other antioxidant biomarkers, including GSH, GPx, and
GR, are also changed during the course of ALS. The levels
of GSH differed in mice carrying different SOD1 mutations.
For example, in SOD1 G93A mutant mice, the GSH level
decreased and the level of GSSG rose in the lumbar spinal
cord [87], while in the same tissue in SOD1 mice with the
Table 2 Clinical trials in ALS patients with agents/drugs showing antioxidant properties
Antioxidant Time point of antioxidant status determination from
the beginning of therapy
Oxidative damage biomarker
change
Reference
Vitamin E (500 mg twice a day) with riluzole
(100 mg/day)
3 months ↑GPx in plasma, ↓TBARS
in plasma
[61]
Selegiline hydrochloride (5 mg twice a day p.o.) 6 months nd [69]
Acetylcysteine (50 mg/kg/day s.c.) 12 months nd [68]
Creatine (5 g twice a day p.o.) 16 months nd [67]
Coenzyme Q10 (1,800 and 2,700 mg/day p.o.) 9 months nd [66]
Edaravone (60 mg/day i.v.) 2 weeks administration every 2 weeks, 6 replications ↓3-NT in CSF [64]
Melatonin (300 mg/day) per rectum 4 months ↓PC in serum [70]
↓ decrease, ↑ increase, nd not determined, 3-NT 3-nitrotyrosine, 8-OHG 8-hydroxyguanosine, CSF cerebrospinal fluid,GPx glutathione peroxidase, i.v.
intravenously, p.o. per os, PC protein carbonyl, s.c. subcutaneous, TBARS thiobarbituric acid reactive substances
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H46R/H48Q mutations, the GSH level was not changed [88].
A recent study by Vargas et al. [88] showed that decreased
GSH content accelerated neurological deficits in the SOD1
G93A mouse model. The mechanism of GSH reduction is
linked to the nuclear transcription factor Nrf2 because its
transfection into the SOD G93A mouse brain led to the up-
regulation of GSH synthesis in astrocytes and reduced the
most apparent neurological and biochemical symptoms of
the disease [89].
In animal models of ALS, motor neurons have displayed
overexpression of Prx2 and glutathione peroxidase-1
(GPx1). The number of neurons containing Prx2 and
GPx1 decreased in the terminal stage of ALS [90], suggest-
ing a breakdown of this redox system at the advanced
stages of the disease. As discussed by Kato et al. [91], a
possible reason for Prx2 and GPx1 breakdown might be
related to the co-aggregation of these enzymes with mutant
SOD1 and the exacerbation of mutant SOD1-mediated tox-
icity in neuronal Lewy body-like hyaline inclusions
(LBHIs), which was shown in the spinal cords of transgenic
rats [91]. Similarly, GPx3 protein levels in the serum of
SOD1 H46R rats were increased in the pre-symptomatic
stage and decreased gradually with disease progression
[55]. However, another study did not reveal significance
for the role of GPx in ALS [92], and further investigation
is therefore necessary to clarify this problem.
Because enhanced SOD activity in ALS animal models
remains enhanced in most of the disease stages and decreases
only to the control level of non-transgenic mice in the end
stage of the disease, this raises the question of whether these
ALS animal models are suitable to study ALS antioxidant
defense biomarkers because an ALS key enzyme, SOD, is
decreased in ALS patients. These contradictory results, ob-
tained in animals and humans, do not allow researchers to
draw conclusions regarding the significance of these bio-
markers in animal ALS models.
Pharmacotherapeutic Strategy to Reduce OS
Many substances possessing antioxidant properties have been
proposed as ALS treatment strategies (Table 4). For example,
coenzyme Q10 was shown recently to be unable to prolong
survival when given after ALS onset [93]. As coenzyme Q10
is characterized by rather poor CNS availability (which pos-
sibly explains its small pharmacological effects), its reduced
form, ubiquinol-10, has better bioavailability and antioxidant
properties and was also investigated. However, similar to its
parent drug, ubiquinol-10 did not prolong lifespan. Neverthe-
less, it was noted that poor CNS availability after oral dosing
was observed in this study, which possibly explains the lack of
pharmacological effects, similar to the case with its parent
drug [93].
Creatine was the next drug that extended survival, but not
age of onset, in ALS animals [94–96]. It has neuroprotective
properties and buffers against ATP depletion in mitochondria.
Its dysfunction can lead to ATP decreases, which may contrib-
ute to cell death [97]. Because mitochondrial swelling and
vacuolization are among the earliest pathological features in
ALS mice with the SOD mutations [98], creatine could be
useful for protecting mitochondria and for disease treatment
in such a preclinical model. In most studies, creatine was
delivered in the diet as a 1 or 2 % food supplementation. In
addition to its effect of prolonging the lifespan in a mouse
ALS model, creatine also improved motor performance [96]
and provided protection frommotor neuron loss at 120 days of
age in these mice [98]. Moreover, creatine was shown to pre-
vent the rise of 3-NT in the spinal cord and ROS production in
the dialysate from microdialysis in ALS animals [98], and it
also had a positive effect on weight retention [99]. However,
one study found that creatine administration had no effect on
the disturbed muscle function [100]. Moreover, co-
administration of creatine with the cyclooxygenase-2 inhibi-
tors rofecoxib and celecoxib or of creatine with minocycline
Table 3 OS biomarkers in ALS
animal model Animal model OS biomarkers Reference
Mice SOD1 G93A-2Gur ↑PC in spinal cord [77]
Mice SOD1 G93A ↑MDA, ↑4-HDA in brain and CSF
Ø MDA, Ø 4-HDA in skeletal muscles and heart
Ø PC in brain, CSF, skeletal muscles, liver, heart
[79]
Mice SOD1 G93A ↑MDA, ↑HNE in spinal cord [81]
Mice SOD1 G93A ↑In vivo trapped radical adducts [76]
Mice SOD1 G93A ↑8-OHdG in spinal cord [80]
Mice SOD1 G93A ↑PC and ↑3-NT in motor and sensory CTX [78]
Rats SOD1 G93A ↑Overnitrated proteins in mononuclear cells from peripheral blood [83]
Mice SOD1 G93A ↑3-NT in spinal cord in presymptomatic stage [82]
↓ decrease, ↑ increase, Ø no changes, nd not determined, 3-NT 3-nitrotyrosine, 4-HDA 4-hydroxyalkenal, 8-
OHdG 8-hydroxy-2′-deoxyguanosine, CSF cerebrospinal fluid, CTX cortex,MDAmalondialdehyde, PC protein
carbonyl
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(a tetracycline antibiotic with neuroprotective and anti-
inflammatory effects) [101] may be even more beneficial for
extending survival (even by 30 %) [94, 96].
Other antioxidants that extended survival in ALS mice
include EUK-8 and EUK-134. In preclinical studies, these
two synthetic SOD/CAT mimetics reduced the levels of
OS, as measured by MDA, PC, and prolonged survival,
but not disease onset, in ALS mice [102]. On the other
hand, treatment with vitamin E significantly delayed ALS
onset with no effect on survival but with a diminishing
effect on 8-hydroxyguanine (8-OHG) levels in the spinal
cord [103]. Drugs that shared both effects (ALS onset de-
lay and lifespan extension) were melatonin, ammonium
tetrathiomolybdate (a copper-chelating drug), and resvera-
trol (a substance that originates in plants and is found in
highest amounts in red wine and the skin of red grapes)
[86, 104–106]. However, in case of melatonin, the data
were not clear as it was given in a dose range of 2.5–
50 mg/kg intraperitoneal (i.p.) (in the same animal model)
and also produced a surprisingly shortened survival, accel-
erated disease onset, enhanced lipid peroxidation in the
spinal cord, and increased spinal motoneuron loss [107].
A possible reason for these results might be due, according
to authors, to melatonin’s effect on upregulating the gene
expression of human toxic SOD1, which presumably
overrides any of the anti-oxidant properties of melatonin.
Such a hypothesis needs to be tested in future studies.
Other substances used in preclinical ALS models,
i.e., resveratrol, which, when given before disease onset,
decreased MDA leve ls [106] , and ammonium
tetrathiomolybdate, which decreased spinal SOD activity
[86]. The latter compound also ameliorated ALS-like
symptoms in SOD1 G93A mice, probably by chelating
the copper ions from the Cys111 site in the SOD-1
enzyme, which is important because various SOD-1 mu-
tations affect Cu and Zn metal-binding, thereby promot-
ing toxic protein aggregation [86]. Moreover, successful
effects were achieved from treatment with ammonium
tetrathiomolybdate when it was given after disease on-
set, which is satisfactory because this regime of admin-
istration closely reflects clinical practice.
Edaravone and AEOL 10150 are recently studied drugs for
ALS that were administered at ALS onset. Although
edaravone did not prolong survival in an ALS mouse model,
it diminished SOD1 deposition in the anterior horn of the
spinal cord and slowed disease progression and motor neuron
degeneration [36]. Another substance that gave more promis-
ing results is AEOL 10150, which, when administered to ALS
mice, decreased 3-NT and MDA levels in the spinal cord,
extended animal survival [108], provided better preservation
Table 4 Therapeutic trials with agents/drugs with antioxidant properties in ALS animal models
Drug, dose, route of administration Animal model Therapy start after Changes in oxidative defense
and damage biomarkers
Onset
change
Survival
change
Reference
Ubiquinol-10 800 mg/kg/day p.o. Mice SOD1 G93A Post-onset nd Ø Ø [93]
Coenzyme Q10 800 mg/kg/day p.o. Mice SOD1 G93A Post-onset nd Ø Ø
Creatine (2 % in diet) Mice SOD1 G93A Pre-onset nd Ø ↑ [95]
Creatine (2 % in diet) + celecoxib
(12 % in diet)
Mice SOD1 G93A Pre-onset nd Ø ↑ [94]
Creatine (2 % in diet) + rofecoxib
(5 % in diet)
Mice SOD1 G93A Pre-onset nd Ø ↑
Creatine (2 % in diet) + minocycline
(22 mg/kg/day i.p.)
Mice SOD1 G93A Pre-onset nd Ø ↑ [96]
Vitamin E 200 IU/day, 5 days/week
for 30 days
Mice SOD1 G93A Pre-onset ↓8-OHG in spinal cord ↑ ø [103]
EUK-8 and EUK-134 33 mg/kg i.p.
3 times a week
Mice SOD1 G93A Pre-onset ↓MDA, ↓PC in spinal cord Ø ↑ [102]
Edaravone 15 mg/kg i.p. Mice SOD1 G93A At symptoms onset ↓abnormal SOD1 deposition
in spinal cord
na Ø [36]
AEOL 10150 2.5 mg/kg i.p. Mice SOD1 G93A At symptoms onset ↓MDA, ↓3-NT in spinal cord na ↑ [108]
Ammonium tetrathiomolybdate
5 mg/kg i.p.
Mice SOD1 G93A Pre-onset ↓LPO, ↓SOD in spinal cord ↑ ↑ [86]
Post-onset nd ↑ ↑ [105]
Resveratrol 25 mg/kg i.p. Mice SOD1 G93A Pre-onset ↓MDA in spinal cord ↑ ↑ [106]
Melatonin 30 mg/kg, 10 μl/g
body weight i.p.
Mice SOD1 G93A Pre-onset nd ↑ ↑ [104]
Melatonin 5 mg/kg, 2.5 mg/kg
or 50 mg/kg i.p.
Mice SOD1 G93A Pre-onset ↑4-HNE, ↑SOD1 in spinal cord ↓ ↓ [107]
↑ increase, ↓ decrease, 0 no change, na not applicable, nd not determined, 3-NT- 3 nitrotyrosine, i.p. intraperitoneally, LPO lipid hydroperoxide, MDA
malondialdehyde, PC protein carbonyls, ROS reactive oxygen species, s.c. subcutaneously, SOD superoxide dismutase
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of motor neuron architecture, and diminished the level of
astrogliosis [108].
In conclusion, according to animal studies, antioxidants
may become putative ALS therapies because many of them
extend the lifespan and diminish OS in ALS animals. How-
ever, it must be remembered that many of them, when tested in
humans, have not yet shown benefits for survival time and
motor function amelioration.
Anti-ALS Drugs that Modulate Oxidative Balance
Riluzole was shown to extend the lifespan in mice in the
SOD1 G93A ALS animal model, but it did not change the
disease onset [109] or have a satisfactory effect on the latter
parameter [110]. No studies concerning oxidative defense or
oxidative damage biomarkers were conducted; however,
in vitro studies showed that riluzole had antioxidant properties
in cultured cortical neurons [111].
Parkinson’s Disease (ICD-10 G20)
PD is a progressive degenerative disorder that is characterized
by the loss of dopamine-producing neurons in the substantia
nigra (SN) and by the presence of Lewy bodies in the SN and
locus coeruleus. Clinical manifestations of PD include resting
tremor, muscle rigidity, slowing of voluntary movements (bra-
dykinesia), a tendency to fall (postural instability), and a
mask-like facial expression [112]. The pathological hallmarks
of PD, Lewy bodies, contain various proteins, including α-
synuclein, ubiquitin, Parkin, and neurofilaments.
PD occurs in sporadic (non-inherited; 90–95 % cases) and
familial (inherited; 5–10 % cases) forms. Mutations in the α-
synuclein gene cause one of the familial forms of PD via
autosomal dominant inheritance [113]. Recently, it was sug-
gested that OS and imbalances between ROS/RNS and anti-
oxidant defense mechanisms are linked to the etiology of PD.
Clinical Studies
Oxidative Biomarkers
Many studies have demonstrated the presence of OS and its
markers in the brain and CSF in PD patients. Cholesterol lipid
hydroperoxide and MDA were found to be up to 10-fold
higher in SN in post-mortem brains of PD patients compared
with other brain regions and age-matched controls [114]. In
contrast, a recent paper demonstrated lower levels of MDA in
the caudate nucleus and putamen and increased MDA levels
in the frontal cortex in the post-mortem analyses of PD brains
compared to healthy age-matched controls. Those results sug-
gested that the non-SN regions, such as the caudate nucleus or
the putamen, may have different compensatory mechanisms
against OS could protect them from oxidative damage [115].
Moreover, HNE and acrolein-modified proteins were found in
the neocortex and brainstem and in the SN, respectively, of PD
patients [116–118]. According to in vitro studies, HNE mod-
ification of α-synuclein has been shown to trigger oligomeri-
zation and fibrillization of unmodified α-synuclein in the ner-
vous system, which might lead to dopaminergic neuron injury.
A recent observation suggests that HNE-modified proteins
should be considered to be important players in PD patho-
physiology [119].
Despite a number of studies supporting lipid peroxidation
in the brains of PD patients, the levels of F2-isoprostanes were
not elevated in the SN of PD patients [120], and the reason for
this observed difference needs to be explained.
PCs were also found in PD patients’ brains compared to
age-matched controls [121]. PCs are present not only in the
brain regions specific for PD (the SN, caudate nucleus, and
putamen) but also in other brain areas not directly linked with
PD. Because most PD patients are treated with L-DOPA, this
observation may suggest that L-DOPA, the Bgold standard^
for PD therapy, may contribute to carbonyl formation because
it was shown to have pro-oxidant properties in vitro [122].
Interestingly, brain regions from individuals with putative pre-
symptomatic PD (incidental Lewy body disease) showed no
PC rise. This information suggests that in PD, oxidative pro-
tein damage occurs late during disease progression and/or that
L-DOPA treatment contributes to carbonyl formation [121].
Oxidative damage to proteins in PD also occurred through
nitration, and 3-NT was found to be increased within Lewy
bodies in the SN pars compacta (SNpc) of PD patients [123].
Another pathology found in PD brains is DNA and RNA
damage [124, 125]. The factors 8-OHG and 8-OHdG were
elevated in various parts of the PD brain compared to controls;
however, the most striking rise was detected in the SN [124,
125]. Similarly, increased levels of 8-OHG and 8-OHdG were
observed in CSF [126, 127]. However, these studies came to
opposite conclusions with respect for the correlation between
8-OHG levels and disease duration.
In the CSF of living PD patients, enhanced levels of HNE
and MDA have been shown as well [128–130], but different
results were obtained by Shukla et al. [131]. Moreover,
markers of oxidative damage in PD patients were also detect-
ed in the serum and urine [132–135], but their use as indica-
tors of the course of the disease is far from being useful for
clinical practice because the existing data are contradictory
[136–138]. As has been suggested [136–138], these differ-
ences may be due to the variability in methods used to mea-
sure OS markers.
The results of many studies have demonstrated the pres-
ence of OS in the brain, CSF, serum, and urine of PD patients;
however, none of the OS markers has been established as a
specific biomarker for PD disease or as a marker for PD dis-
ease progression.
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Antioxidant Defense Biomarkers
PD is characterized by a selective loss of GSH in the SN (40%
compared to control subjects) but not in other parts of the
brain [139]. This decrease is one of the earliest biochemical
changes that has been observed in the disease [140–143], and
it results in a selective drop in mitochondrial complex I activ-
ity, another hallmark of PD [144]. On the other hand, a sub-
stantial rise in SOD levels has been observed in the SN and
basal ganglia in PD patients [145], while no change in activ-
ities of CAT, GPx, and GR was found compared to age-
matched controls [145]. Another study showed some deficien-
cy in GPx in the SN in Parkinsonian patients [146], but the
weak (ca. 19 %) reduction in such a small number of patients
(n=11) cannot be considered to be conclusive. Another small
pilot study in PD patients (n=8) indicated a peripheral (in
blood) increase in GSH/GSSG [147] when the patients went
off of PD medications (dopamine receptor agonists) for 12 h
in comparison to GSH/GSSG levels when they were on med-
ications. This suggests that PD medications may play a disad-
vantageous role that leads to enhanced peripheral oxidative
stress; however, the small sample size excludes a final conclu-
sion [147].
Pharmacological Strategies to Reduce OS
Because there is an overwhelming amount of evidence
showing that OS and NS in PD patients leads to an increase
in pathological damage in the SN, many approaches have
been attempted to reduce ROS/RNS production. One of the
possible strategies was to supplement GSH. As shown by
Sechi et al. [148], in nine patients in the early stage of the
disease [148], GSH (600 mg twice daily) administered in-
travenously for 30 days reduced (by 42 %) the clinical
disability of PD patients, and this effect lasted for 2–
4 months. Furthermore, a recent study of N-acetylcysteine
(150 mg/kg), which is a GSH precursor, revealed an eleva-
tion in brain GSH levels and the blood GSH/GSSG ratio
after 1-h of intravenous (i.v.) infusion [149]. Unfortunately,
no results concerning the clinical status of PD patients have
been described. However, N-acetylcysteine, in a smaller
dose (70 mg/kg p.o., every 12 h over 2 days), produced
negligible changes in GSH levels in the CSF and no imme-
diate improvement to symptoms (according to the Unified
Parkinson’s Disease Rating Scale and the Montreal Cogni-
tive Assessment) [150].
Magnetic resonance imaging (MRI) studies showed a
rise in iron concentrations in the SN in PD patients [151].
Because iron can lead to ROS production in PD patients,
an iron-binding compound, deferiprone, has been tested in
a pilot study in PD patients (FAIRPARK trial, registered as
ClinicalTrials.gov NCT00943748). Patients in early-stage
PD who were on a stabilized dopamine regimen received
deferiprone (30 mg/kg/day) for 12 months (early-start par-
adigm, n=19), while the other group received the drug for
only 6 months, with the latter, shorter therapy starting
6 months later than the early-start paradigm (delayed-start
paradigm, n=18) [152]. The earlier therapy start dimin-
ished SN iron deposits to a greater extent than the
delayed-start paradigm and improved motor performance
vs. placebo and vs. the delayed-start paradigm, according
to the Unified Parkinson’s Disease Rating Scale [152].
Moreover, in deferiprone-treated patients, GPx and SOD
activity in the CSF increased, which supports the connec-
tion between the chelator treatment and the antioxidant
response.
Vitamin E (α-tocopherol) was also suggested as a way to
diminish the OS and to reduce clinical symptoms in PD. How-
ever, the clinical trial The Deprenyl and Tocopherol Antioxi-
dant Therapy of Parkinsonism study (DATATOP study) re-
vealed no evidence of any beneficial effect for α-tocopherol
(2,000 IU/day) in either slowing functional declines or ame-
liorating the clinical features of Parkinson’s disease. It is of
note that no analysis of OS biomarkers was performed in that
trial [153, 154]. Since DATATOP, no clinical trials using vita-
min E as a potential PD medication have been conducted. In
fact, vitamin E was only used in PD clinical trials as a supple-
ment for coenzyme Q10 or as a placebo [155] or a control
[156].
Another potent antioxidant, coenzyme Q10 (1200 mg a
day), in the first reported multicenter, randomized, placebo-
controlled, and double-blind trial slowed functional declines
compared to placebo [157]. Lower doses or different formu-
lations of coenzymeQ10 displayed no symptomatic effects on
midstage PD [158]. Recent clinical trial did not show a benefit
for coenzyme Q10 (1,200 or 2,400 mg/day) in 600 patients in
early-stage PD [155].
An early clinical study on creatine monohydrate (10 g/day
for 12 months) in 67 subjects who were within 5 years of a PD
diagnosis showed some positive results for treating behavioral
difficulties [159], and an additional 18-month follow-up study
confirmed this finding [160]. On the other hand, a smaller (n=
31 creatine PD group, n=17 placebo PD group), but longer, 2-
year clinical trial demonstrated that creatine had no effect on
PD scores or dopamine transporter imaging [161]. In Septem-
ber 2013, the NINDS discontinued the NET-PD LS-1 study
(phase III clinical trial with a total of 1,720 planned partici-
pants, ClinicalTrials.gov identifier: NCT00449865) that
started in 2007 because the results obtained from a study of
creatine used for the treatment of early stage PD did not dem-
onstrate a statistically significant difference between the active
substance and placebo [162].
In conclusion, although evidence for the link between OS
and damage in PD is overwhelming, suggesting the potential
efficacy of antioxidant drugs, most clinical trials have so far
failed to support this statement.
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Anti-Parkinsonian Strategies to Restore Oxidative
Balance
Administration of zonisamide, an anticonvulsant drug pre-
scribed to treat resting tremor in PD, inhibited the rise of 8-
OHdG levels in the urine of PD patients. As the 8-OHdG rise
correlates with disease progression and aging, it can be pre-
sumed that zonisamide could be helpful in defending against
OS-evoked DNA modifications in PD patients. Other drugs
used for treatment of PD (i.e., L-DOPA,monoamine oxidase B
(MAO-B) inhibitors, catechol-O-methyltransferase (COMT)
inhibitors, and the dopamine receptor agonists ropinirole and
pramipexole) have not shown such properties [163].
Interesting findings were reported in a study that measured
GSH levels in venous blood in PD subjects who were on- and
off-medication while performing acute physical exercises, be-
cause we know that this type of physical activity leads to GSH
depletion and GSSG rise [164]. Surprisingly, the off-
medication patients had a lower drop in GSH level than the
on-medication group. This finding suggests that patients in the
off-medication state handled acute stress better than those in
the on-medication state, indicating that medication may im-
pede the ability to tolerate acute OS [165]. Similar conclusions
were obtained in a very recent study by Nikolova et al. [166],
who observed a greater rise in PC and 8-OHdG levels in the
blood of PD patients who were treated with L-DOPA in com-
parison to untreated PD patients, demonstrating that adminis-
tration of L-DOPA may cause greater OS than PD itself [166].
Animal Studies
Oxidative Biomarkers
The most popular animal models of PD include pharmacolog-
ical (6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,
3,6-tetrahydropyridine (MPTP), rotenone, and paraquat) as
well as several genetic (with mutations in the α-synuclein,
PINK1, Parkin, or LRRK2 genes) models [167].
The 6-OHDA model (Table 5), wherein the toxin is
injected directly into the SNpc, medial forebrain bundle, or
striatum, was the first animal model of PD associated with
dopaminergic neuronal death within the SNpc [168].
Another PD model utilizes MPTP, a highly lipophilic mol-
ecule that rapidly crosses the blood–brain barrier, leading to an
irreversible and selective loss of dopaminergic neurons in the
SN in non-human primates [169, 170] and in rodents [162,
171], although the latter species was less sensitive to MPTP
than primates [172]. Other chemical models are based on an
insecticide, rotenone, or paraquat, an herbicide. Rotenone,
when given i.v. in a low dose to rats, produces selective de-
generation of SN dopaminergic neurons that is accompanied
by α synuclein-positive LB-like inclusions [173]. Paraquat is
used less widely than MPTP, rotenone, or 6-OHDA models
and is used instead as an addition to other toxic agents, such as
the fungicide maneb [174]. It was reported to cause selective
degeneration of nigrostriatal dopaminergic neurons in mice
[175]. The mechanism of action of MPTP (a precursor form
of the reactive metabolite MPP+), rotenone, or paraquat is
based on the inhibition of mitochondrial complex I, which
leads to ROS production [167, 174, 175].
As has been demonstrated in numerous studies, OS is
widely present in all of these toxin-based models (see
Table 5). 6-OHDA, when injected into the striatum, in-
creased MDA, HNE, PC, and 3-NT levels in this structure
and increased TBARS in SN [176–179]. Similarly, in the
MPTP and in the rotenone models, elevated levels of lipid
peroxidation products [180–185] and oxidatively modified
proteins [185, 186] were observed in various parts of the
brain (striatum, cortex, SN, hippocampus, cerebellum, and
midbrain). In addition to lipid damage, increased3-NT levels
were also detected following the use of MPTP in the SN,
striatum, and ventral midbrain [181, 187]. MPTP or
rotenone-treated animals also showed oxidatively modified
RNA or DNA in the SN or striatum [185, 188, 189]. In the
paraquat andmanebPDmodels, enhanced lipid peroxidation
in the nigrostriatal areas of animal brains was also shown
[190] (Table 5). A very recent report from Kumar et al.
[175] demonstrated for the first time thatα-synuclein radical
is formed in the midbrain in paraquat- and maneb-treated
mice, indicating that radical formation is mediated by
peroxynitrite and depends on both NADPH oxidase and
iNOS. This interesting result regarding α-synuclein radical
formation was obtained by using the immuno-spin trapping
method in combination with immunoprecipitation [175].
Moreover, it was noted that protein radicals such as α-
synuclein radical may trigger protein aggregation, which
plays a causal role in dopaminergic neuronal death [175].
For review of genetic models and OS, see the excellent
paper [167].
All toxin-based models share common characteristics, in-
cluding the ability to produce ROS and further oxidative dam-
age, which causes death in dopaminergic neurons and reflects
part of the pathology observed in PD. Although all of those
models have drawbacks, they are useful for testing neuropro-
tective therapies.
Antioxidant Defense Biomarkers
A characteristic shared feature observed in all toxin-based
models is a drop in GSH level in key PD structures [177,
183–187, 191–196] (Table 5). Importantly, lower GSH levels
make nigrostriatal neurons more susceptible to oxidative dam-
age and further degeneration.
Studies using 6-OHDA also showed a reduction in activity
by SOD, CAT, and glutathione S-transferase (GST) in striatum
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and SN [177, 178, 191]. On the other hand, results from the
MPTP model are inconclusive regarding SOD and CATactiv-
ity. Moreover, some of the MPTP studies showed increased
SOD activity in the SN [192] and striatum [183], while others
reported diminished SOD activity in these regions [180, 197].
These differences may have resulted from the use of different
doses of the toxin, varied routes of drug administration (intra-
cranial versus i.p. or s.c.), and different use of rodent species in
the studies (see Table 5).
Similar to SOD activity, CATactivity cannot be considered
a biomarker of OS in rodent PDmodels as its activity was both
diminished [182, 191, 193, 194, 196, 197] and enhanced
[184]. Moreover, GPx activity was diminished in striatum in
an MPTP model [197], while GST activity was found to be
elevated in a maneb and paraquat PD animal model [190]
(Table 5).
All of these reports on the enhanced activities of SOD,
CAT, and GST suggest the presence of mechanisms in brain
Table 5 Changes in OS and anti-OS defense biomarkers in toxin-based model of PD
Animal
model
Route of administration,
dosage
Animal species OS biomarkers Oxidative defense biomarkers Reference
6-OHDA Unilateral intra-STR inj.
10 μg/2 μl
Rats (Wistar) ↑TBARS in SN ↓GSH, ↓CAT ↓SOD in SN [191]
Bilateral intra-STR inj.
10 μg/2 μl
Rats (Fischer) ↑HNE, ↑PC in STR nd [176]
Unilateral intra-STR inj.
300 μg/10 μl
Rats (Sprague-
Dawley)
↑PC in STR ↓GSH and ↓SOD in STR [177]
Intra-STR inj. 8 mg/2 ml Rats (Wistar) ↑MDA in STR ↓SOD, GST in STR [178]
Intra-STR inj. 8 μg/4 μl Rats (Wistar) ↑3-NT, ↑HNE in STR nd [179]
MPTP 20 μl/kg intra-SN inj. Rats (Wistar) ↑MDA in SN ↓SOD in SN [180]
25 mg/kg/day for 5 days Mice (C57BL/6) ↑iNOS, ↑HNE, ↑3-NT in SN nd [181]
Intra-SN inj. Rats (Wistar) ↑MDA, ↑nitrate in STR and CTX ↓GSSH, ↓CAT in STR and CTX [182]
24 mg/kg sc. for 6 days Mice (C57BL/6) ↑MDA in STR ↓GSH, ↓SOD, ↓GPx, ↓CAT in STR [197]
100 μg/1 μl, bilateral infusions Rats (Wistar) ↑LPO in STR ↓GSH, ↑SOD in STR [183]
15 mg/kg s.c. for 3 days Mice (C57BL/6) ↑3-NT, ↑HNE in ventral midbrain ↓GSH, ↑GSSG in ventral midbrain [187]
24 mg/kg s.c. (2 times/day at
12-h interval) for 2 days
Mice (C57BL/6) ↑8-OHG in SN nd [188]
20 mg/kg i.p. 3 times at 2-h
interval
Mice (C57BL/6J) ↑8-OHG in STR nd [189]
30 μg/kg i.p. 2 times at 16-h
interval
Mice (Balb/c) nd ↓GSH, ↑SOD in SN, nucleus
caudate, and putamen
[192]
Rotenone 2.5 mg/kg, i.p., for 10 days Rats (Wistar) nd ↓GSH in HIP, ↓CAT in HIP and STR [193]
One-sided intra-SN inj. 6 μg Rats (Sprague-
Dawley)
nd ↓GSH, ↑Cu-Zn SOD, ↑CAT in SN,
Ø GSH, Ø SOD in STR
[194]
3 mg/kg i.p. for 30 days Rats (Wistar) nd ↓GSH, ↓SOD in STR [195]
2 mg/kg s.c. for 35 days Rats (Sprague-
Dawley)
↑TBARS, ↑SAG in the midbrain
regions and cerebellum
and CTX
↓GSH, ↓CAT in midbrain [196]
2 mg/kg s.c. for 35 days Rats (Sprague-
Dawley)
↑MDA in midbrain regions and
cerebellum
↓GSH, ↓SOD, and ↑CAT in midbrain
and CTX ↑NO in midbrain
[184]
1 mg/kg i.p for 3 weeks Mice (CFT-
Swiss)
↑PC in HIP, CTX, STR ↓GSH, ↓TT in HIP, ↓GPx, ↓CAT in
CTX and HIP, ↓SOD in CTX and
STR
[186]
1.5 mg/kg/48 h s.c., 6 doses Rats (Albino) ↑LPO, ↑PC, ↓mtDNA in STR ↓GSH, ↓SOD in STR [185]
Paraquat +
maneb
Paraquat (10 mg/kg) + maneb
(30 mg/kg), twice a week,
for 9 weeks
Mice (Swiss
albino)
↑MDA, ↑NO in nigrostriatal
tissues
↑GST in nigrostriatal regions [190]
Paraquat (10 mg/kg, i.p.), and
maneb (30 mg/kg, i.p.),
twice a week, for 6 weeks
Mice (C57BL6/J) α-Synuclein radical in the
midbrain
nd [175]
↑ increase, ↓ decrease, Ø no change, nd not determined, 6-OHDA 6-hydroxydopamine, CAT catalase, CTX cortex, GPx glutathione peroxidase, GSH
glutathione,GST glutathione S-transferase, HIP hippocampus,HNE 4-hydroxynonenal, i.c.v. intracerebroventricular, intra-SN inj. intra-substantia nigra
injection, LPO lipid hydroperoxide,MDA malonyldialdehyde,MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, NO nitric oxide, NOS nitric oxide
synthetase, PC protein carbonyl, SAG superoxide anion generation, s.c. subcutaneous, SN substantia nigra, SOD superoxide dismutase, STR striatum,
TBARS thiobarbituric acid reactive substances
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areas that defend against exposure to PD toxin models. On the
other hand, diminished activities or levels of antioxidant en-
zymes may indicate that these defense mechanisms were over-
come and that the degeneration process had begun.
Pharmacotherapeutic Strategy to Reduce OS
Several agents, such as valproic acid [178] and melatonin
[198], effectively reversed changes in antioxidant defense bio-
markers and oxidative damage in the 6-OHDA rat model of
PD (Table 6).
There are also data in the literature showing that other
agents and drugs have antioxidant activity (i.e., ceftriaxone
[182] and N-acetylcysteine [199], which decreased oxidative
damage and/or enhanced antioxidant defense biomarkers in
the striatum, cortex or SN in rodent MPTP models).
Ibuprofen (a non-steroidal anti-inflammatory drug [193]),
acetyl-L-carnitine (a natural compound reported to prevent
mitochondrial injury deriving from oxidative damage
in vivo), α-lipoic acid (given alone or in combination with
acetyl-L-carnitine [185]), and centrophenoxine (a potent noot-
ropic agent that acts as an antioxidant) [184] were demonstrat-
ed to enhance GSH levels and CAT and SOD activity and to
Table 6 Therapeutic trials with substances possessing antioxidant properties in PD animal models and their influence on changes of biomarkers of OS
and anti-oxidative defense
Model Biomarkers of OS and anti-
oxidative defense
Drug and route of
administration
Changes in biomarkers of OS and
anti-oxidative defense
Reference
6-OHDA, rats (Wistar) ↑MDA, ↓SOD, ↓GPx, ↓CAT
in STR
Melatonin (10 mg/kg i.p.
for 30 days)
↓MDA, ↑SOD, ↑GPx, ↑CAT in STR [198]
6-OHDA, 8 mg/2 ml
intra-STR inj., rats
↑MDA, ↓SOD, ↓GST in STR Valproic acid (300 mg/kg)
i.p. for 10 days
↓MDA, ↑SOD in STR [178]
MTPT intra-SN inj., rats ↓GSH, ↓CAT, ↑nitrate, ↑LPO
in STR and CTX
Ceftriaxone (100 mg/kg
or 200 mg/kg i.p.)
↑GSH, ↑CAT, ↓nitrate, ↓LPO in STR
and CTX
[182]
Ceftriaxone (100 mg/kg i.p.
and ropinirol 1, 5 or
3 mg/kg i.p.)
↑GSH, ↑CAT, ↓nitrate, ↓LPO in STR
and
MPTP mice (C57BL/6J), ↑LPO, ↑SOD, ↓GPx, ↓GSH
in SNpc
N-acetylcysteine ↓LPO, ↓SOD, ↑GPx, ↑GSH in SNpc [199]
Rotenone, 2.5 mg/kg, i.p.
for 10 days, rats
↓GSH in HIP, ↓CAT in HIP
and STR
Ibuprofen (15 mg/kg, p.o.
22 days post 10-day
rotenone treatment)
↑GSH in HIP vs. rotenone group, ↑CAT
in HIP and STR vs. rotenone group
[193]
Rotenone, 3 mg/kg i.p.
for 30 days, rats
↓GSH, ↓SOD, ↑MDA in STR Lycopene (10 mg/kg, p.o.
for 30 days, a combined
treatment with rotenone)
↑GSH, ↓SOD, ↑CAT in HIP, STR [195]
Rotenone, 1 mg/kg/day
i.p. for 3 weeks, mice
(CFT-Swiss)
↓GSH in HIP, ↓TT in HIP, ↓GPx,
↓CAT in CTX and HIP, ↓SOD
in CTX and STR, ↑PC in HIP,
CTX, STR
TSE—aqueous extract of
tomato seeds (100 mg/
kg p.o. for 3 weeks, 1 h
before rotenone injection)
↑GSH, ↑CAT, ↑TT in HIP, ↓PC in STR,
↑SOD in CTX and STR, ↑GPx in
CTX and HIP ↓PC in STR, ↑SOD
in CTX and STR
[186]
Rotenone, 1.5 mg/kg/48
h/6 doses, s.c., rats
(Albino)
↑LPO, ↑PC, ↓GSH, SOD, ↓
mtDNA in STR
Acetyl-L-carnitine (100 mg/
kg/day, p.o.), α-lipoic acid
(50 mg/kg/day, p.o.) or
their combination
↓LPO, ↑GSH, ↑SOD, and ↑mtDNA in
STR after each drug alone or after
combination, ↓PC, ↑CAT in STR
only after combination
[185]
Rotenone, 2 mg/kg s.c.
for 35 days, rats
(Spraque- Dawley)
↑MDA in midbrain and
cerebellum, ↓GSH, ↓SOD,
and ↑CAT in midbrain and
CTX, ↑NO in midbrain
Centrophenoxine (100 mg/kg
i.p., co-administration with
rotenone for 35 days)
↓MDA in midbrain and cerebellum, ↑
GSH, ↑SOD,↑CAT in midbrain and
CTX,↓NO in midbrain
[184]
Maneb (30 mg/kg) and
paraquat (10 mg/kg)
i.p. twice a week
for 9 weeks, mice
(Swiss albino)
↑MDA, ↑NO, ↑GST in
nigrostriatal regions
Silymarin (40 mg/kg i.p. for
9 weeks), maneb, and
paraquat were administered
2 h after this injection
↓MDA, ↓NO, and ↓GST in nigrostriatal
tissues
[190]
Melatonin (30 mg/kg i.p. for
9 weeks, maneb and
paraquat were administered
2 h after this injection
↑ increase, ↓ decrease, nd not determined, CAT catalase, CTX cortex, GPx glutathione peroxidase, GSH glutathione, GST glutathione transferase, GST
glutathione S-transferase, HIP hippocampus, HNE 4-hydroxynonenal, i.c.v. intracerebroventricular, i.p. intraperitoneal, intra-SNc inj. intra-substantia
nigra injection, intra-STR inj. intrastriatal injection, LPO lipid hydroperoxide,MDA malonyldialdehyde, NO nitric oxide, NOS nitric oxide synthetase,
PC protein carbonyl, s.c. subcutaneous, SN substantia nigra, SNpc substantia nigra pars compacta, SOD superoxide dismutase, STR striatum, TBARS
thiobarbituric acid reactive substances, TT total thiol
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decrease lipid peroxidation in investigated brain regions in a
rat rotenone model (Table 6).
Prevention of oxidative damage and the presence of antioxi-
dant defense biomarkers have been documented following treat-
ment with natural compounds, such as lycopene [195], aqueous
extract of tomato seeds (TSE) [186], and melatonin [190].
Many different agents may improve antioxidant brain sta-
tus in different PD models. However, it should be noted that
most of these agents were given before or concomitantly with
rotenone, MPTP, or other PD-causing toxins. To definitively
answer whether these agents can also show efficacy in reduc-
ing the consequences of exposure to prior administration of
PD-inducing toxins, further studies are required. This is espe-
cially true because the latter type of drug administration would
be a better model for evaluating any pharmacological strategy
for reducing OS in PD patients.
Anti-Parkinsonian Drugs that Modulate Oxidative
Balance
Most anti-parkinsonian drugs may improve brain antioxidant
status in PD preclinical tests (Table 7). Ropinirole, a second-
generation, non-ergoline dopamine receptor agonist with D2-
like receptor selectivity and a chemical structure similar to that
of dopamine was found to enhance GSH levels and CAT [182]
activity and to diminish nitrate levels [182] in the striatum in
MPTP-lesioned animals.
Other anti-parkinsonian drugs, such as selegiline (a selec-
tive irreversibleMAO-B inhibitor) [196], deferoxamine [177],
and pramipexole (a non-ergoline dopamine agonist) [200],
increased GSH levels in the striatum, SN, or cortex. Deferox-
amine also decreased a protein oxidative damage biomarker
[177] and enhanced SOD activity in the striatum, while
selegiline reduced superoxide anion generation (SAG) and
increased CAT activity in midbrain regions and the cortex
[196]. Interestingly, L-DOPA, the most commonly used drug
in PD treatment, did not restore the reduced GSH levels in the
SN in the MPTP mouse model [200].
The above studies suggest that antiparkinsonian drugs,
with the exception of L-DOPA, display some antioxidant
properties, which may be considered as part of their mode of
action and efficacy in PD treatment.
Alzheimer’s Disease (ICD-10 G30)
AD is themost common neurodegenerative disease and is char-
acterized by memory loss, dysfunctions in cognitive abilities
(e.g., executive function, attention, language, and visuospatial
skills), confusion, aggression, and mood swings [113, 201] and
leads to death within 5 to 9 years after the diagnosis [202].
The pathogenesis of AD is not yet clearly understood. The
aggregation of extracellular insoluble protein plaques (com-
posed of beta amyloid (Aβ)) and intracellular neurofibrillary
tangles (NFTs, composed of tau protein) are critical hallmarks
of AD [113, 201]. However, many ongoing pathological pro-
cesses lead to regional neuron loss, beginning in the medial
temporal lobe [201] and following in other brain regions, such
as the hippocampus and cerebral cortex [113].
Many clinical trials and animal studies have recognized free
radicals as mediators of injury in AD patients and AD models.
Table 7 Therapeutic trials with anti-parkinsonian drugs in PD animal models and their influence on biomarkers of OS and of anti-oxidative defense
Model Oxidative defense biomarkers Drug Changes in oxidative
defense biomarkers
Reference
MPTP 25 mg/kg i.p. for
5 days administered to
6C57BL/6J mouse
↓GSH in SN L-DOPA (200 mg/kg i.p. 2 injections/
day for 4 weeks, co-administration
with MPTP
Ø GSH in SN [200]
MPTP 1 μmol/2 μl intra-
SN administered to
Wistar rat
↓GSH, ↓CAT, ↑nitrate, and
↑LPO in STR and CTX
Ropinirole 1, 5, or 3 mg/kg i.p. for
14 days, after MPTP treatment
↑GSH, ↑CAT, ↓nitrate
(only 1.5 mg/kg)
in STR and CTX
[182]
MPTP 25 mg/kg i.p. for
5 days administered to
C57BL/6J mouse
↓GSH in SN Pramipexole 1 mg/kg i.p. 2 injections/
day for 4 weeks, co-administration
with MPTP
↑GSH in SN [200]
Rotenone 2 mg/kg s.c.
35 days administered
to Sprague-Dawley rats
↑TBARS, ↑SAG in midbrain
regions and cerebellum,
↓GSH and ↓CAT in
midbrain regions and CTX
Deprenyl 10 mg/kg p.o. co-
administration with rotenone
for 35 days
↓TBARS, ↓SAG in
midbrain; ↑GSH, ↑
CAT in midbrain
and CTX
[196]
6-OHDA 300 μg/10 μl
unilateral intra-STR inj.
administered to Sprague-
Dawley rats
↑PC, ↓GSH, and ↓SOD in STR Deferoxamine 50 mg/kg p.o. for
14 days, co-administration with
6-OHDA
↓PC, ↑GSH, and ↑SOD
in STR
[177]
↑ increase, ↓ decrease, Ø no change, na not applicable, 6-OHDA 6-hydroxydopamine, CAT catalase, CTX cortex, GSH glutathione, i.p. intraperitoneal,
LPO lipid hydroperoxide, MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, PC protein carbonyl, s.c. subcutaneous, SAG superoxide anion gener-
ation, SOD superoxide dismutase, STR striatum, TBARS thiobarbituric acid reactive substances
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Clinical Studies
Oxidative Biomarkers
The first report of the involvement of OS in AD pathology
came from a paper by Martins et al. [203], in which elevated
activities of glucose-6-phosphate dehydrogenase and 6-
phosphogluconate dehydrogenase were documented in post-
mortem studies of brains of AD patients compared to age-
matched controls [203]. The latter increase was proposed to
be a response to enhanced brain peroxide metabolism.
Other post-mortem studies on brains and CSF from AD
patients showed ROS-mediated injuries. For instance, AD pa-
tients had increased levels of MDA and HNE, iso- and
neuroprostanes, and acrolein compared to controls [204]. It
was suggested that these peroxidated lipids formed adducts
with proteins and that they might thereby play a role in AD
pathogenesis [201].
In addition to lipids, protein damage due to OS has also
been reported in AD. In fact, increased PC levels in the frontal
and parietal cortices and the hippocampus were found in post-
mortem studies of the brains of AD patients, while PC was
absent in the cerebellum, where no AD pathology was present
[205]. Furthermore, evidence of oxidative DNA modification
was found in AD patients as an increase in 8-OHG in human
brain homogenates [201].
In AD patients, ROS production seems to be enhanced;
furthermore, increases in RNS were also detected. Such evi-
dence of RNS modification was identified both in astrocytes
and in neurons in AD patient brains examined post-mortem
[206]. The changes in astrocytes were found to co-localize
with an increase in iNOS, eNOS, and nNOS expression. The
latter increases were noted specifically in cortical pyramidal
cells [206]. In another study, increased expression of iNOS
and eNOS was observed to be directly associated with Aβ
deposits, showing that beta amyloid might induce NOS to
produce NO, which might lead to 3-NT formation [207].
The presence of 3-NT was also reported in the cerebral
blood vessels of AD patients post-mortem [206]. These find-
ings were associated with reduced NO bioavailability in plas-
ma and further hypoperfusion in AD patients because NO
promotes vascular smooth muscle relaxation and thereby reg-
ulates blood flow. As was reported in recent studies, enhanced
NO production is a likely cause of production of ONOO−
[208, 209].
Another set of oxidative damage biomarkers, 8-OHdG and
8-OHG, were elevated in AD ventricular CSF [210] and in
brains in both mitochondrial and nuclear DNA compared with
age-matched controls [211].
Consistent data showing enhanced levels of MDA, HNE,
iso- and neuroprostanes, acrolein, PC, 8-OHG, 8-OHdG, and
3-NT in the CNS of AD patients can be considered to be proof
that OS and NOS are significant contributors to brain damage.
Antioxidant Defense Biomarkers
Pivotal antioxidant enzymes, including GPx, CAT, and SOD,
display changed levels in the brains of AD patients [212, 213].
However, the data are not consistent. For instance, elevated
levels of antioxidant enzymes (mainly SOD) in the hippocam-
pus and amygdala of AD patients have been reported [208].
On the other hand, in AD patients, decreased levels of SOD,
GPx, and CAT were found in the frontal and temporal cortex
[214], while decreases in GSH were observed in the brain and
erythrocytes of AD patients [212, 213]. Evidence in support of
changes in antioxidant enzymes comes from a recent study
that identified genetic polymorphisms in the GPx-1 and GST
genes that were positive risk factors for AD [215, 216].
The GSH levels were reduced not only in AD but also in
mild cognitive impairment (MCI), which is considered to be a
preclinical stage of AD [217]. MCI patients also showed a
decreased GSH/GSSG ratio and a reduction in SOD and
GST activity in the hippocampus compared to age-matched
controls [218], which suggests that alterations in GSH metab-
olism may be considered as an early biomarker of AD onset.
The plasma levels of antioxidants, such as albumin, biliru-
bin, uric acid, lycopene, vitamin A, vitamin C, and vitamin E,
are decreased in AD patients [219, 220], although there are
some reports indicating the opposite direction of these chang-
es [221]. Differences in results might be caused by measure-
ment of antioxidants at different disease stages (fully devel-
oped disease vs. subclinical stage of the disease) [219–221].
Pharmacological Strategy to Reduce OS
As OS is present in AD patients, some clinical studies have
aimed to test the ability of antioxidant substances to diminish
ROS production and to alleviate or to slow the course of the
disorder (Table 8).
Most studies on the effects of the administration of vita-
mins that possess antioxidant activity have provided inconclu-
sive information showing that they diminished lipid peroxida-
tion in CSF but had no positive effects on cognitive or func-
tional aspects. For example, AD patients taking cholinesterase
inhibitors and vitamin C (1,000mg/day) or vitamin E (400 IU/
day) supplements for 1 year showed decreased CSF oxidation,
but no difference in cognition was observed [222]. Similarly,
16-week treatment with a combination of vitamin E (800 IU/
day), vitamin C (500 mg/day) and α-lipoic acid (900 mg/day)
decreased CSF F2-isoprostane levels, which suggested a re-
duction of OS in the brain, but surprisingly, this therapy ac-
celerated cognitive decline (according to Mini-Mental State
Examination scores), leading to the conclusion that a combi-
nation of antioxidants should not be used for AD therapy
[223]. On the other hand, very recent results from a large,
clinical, double-blind, randomized trial (TEAM-AD VA,
NCT00235716) showed that a much larger dose of vitamin
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E (2,000 IU/day) than was used in previous trials resulted in a
slower functional decline compared with placebo in mild to
moderate AD [224]. Although the latter study suggests that
vitamin E can have a positive influence on AD, no OS bio-
markers have been measured in parallel in the AD patients
who participated in that trial, which limits the final conclusion.
Administration of other antioxidants, including coenzyme
Q10 as well as its synthetic analogue, idebenone (which pos-
sesses a better ability to pass the blood–brain barrier), in AD
patients did not provide any positive results with regards to the
volume of ROS-dependent tissue damage or cognitive func-
tion improvements [223, 225]. Similarly, administration of
omega-3 (ω-3) fatty acids also did not yield a positive out-
come for slowing the rate of decline of cognitive (Mental State
Examination (MMSE); Alzheimer’s Disease Assessment
Scale—cognitive subscale) or functional (Activities of Daily
Living/Instrumental Activities of Daily Living) abilities [226,
227]. Different results were reported in a recent study, where
12-month ω-3 fatty acid supplementation caused a delay in
progression of functional impairment in AD patients, while
combined supplementation of ω-3 and α-lipoic acid resulted
in slowing global cognitive declines (MMSE) [228]. Al-
though positive cognitive outcomes were obtained, no chang-
es after ω-3 or ω-3 plus α-lipoic acid supplementation were
observed in OS biomarkers, suggesting a different mechanism
for their actions that lead to improved cognitive and functional
measures [228].
Curcumin, which is a natural polyphenolic compound and
an in vitro blocker of Aβ aggregation, did not diminish the
enhancement of F2-isoprostane levels in the CSF [229] or
plasma [230], or the Aβ1–40 level in plasma [230], and it did
not ameliorate neuropsychological test results in AD patients
[229, 230]. As suggested by Ringman et al. [229], low bio-
availability of the drug and low plasma levels due to poor
uptake from the gastrointestinal tract might be the reasons
for its lack of efficacy in the latter studies. There is some hope
that curcumin efficacy can be improved through the use of its
lipidated forms, which are predicted to have better uptake
compared to the nonlipidated form [231]. In a study in healthy,
middle-aged volunteers, the lipidated form of curcumin
(80 mg/day) decreased Aβ1–40 levels in plasma [231], sug-
gesting that further trials using lipidated curcumin should be
considered in AD patients.
More promising results came from a study using resvera-
trol. The Copenhagen City Heart Study reported that monthly
or weekly consumption of red wine was associated with a
lower risk of dementia [232]. The clinical study
NCT01504854, also called the BPhase II Study to Evaluate
the Impact on Biomarkers of Resveratrol Treatment in Patients
with Mild to Moderate AD,^ was undertaken in 2011 to eval-
uate the effectiveness of resveratrol for changing AD CSF
biomarkers (total tau, Aβ42, Aβ40, and phospho-tau181), the
effect of resveratrol treatment on hippocampal atrophy and
regional cortical thinning, and the influence of resveratrol ad-
ministration on the outcomes of several clinical scales used to
assess the severity of dementia [233]. According to the report
at http://clinicaltrials.gov record (accessed 15 May 2015), the
study has been completed, but no results have yet been
published.
Anti-Alzheimer’s Disease Therapy and Oxidative Balance
Acetylcholinesterase (AChE) inhibitors (donepezil,
rivastigmine, galantamine, and tacrine) and the NMDA recep-
tor antagonist memantine are the most commonly used drugs in
AD pharmacotherapy. Only some clinical studies that have
investigated the influence of these drugs on oxidative balance
in AD patients are currently available (see Table 9). One of
them showed no positive effects of AChE inhibitors on OS
parameters (CAT and GR levels) in the blood of AD patients
compared with AD drug-naïve patients [234]. In another study,
donepezil enhancedGSH levels, while rivastigmine diminished
advanced glycation end products (AGEs) in the plasma of AD
patients. However, other examined parameters, namely total
Table 8 Clinical trials with substances/drugs with antioxidant properties in AD patients
Antioxidant Duration
of therapy
Oxidative damage biomarker change Reference
Vitamin E (α-tocopherol, 800 IU/day) + vitamin C (500 mg/day)
+ α-lipoic acid (900 mg/day)
16 weeks ↓F2-isoprostane in CSF [223]
Coenzyme Q10 (400 mg×3 times/day) 16 weeks Ø F2-isoprostane in CSF [223]
ω-3 (3 g/day contained 675 mg DHA and 975 mg EPA) 12 months Ø F2-isoprostane in urine, Ø PC in plasma [228]
ω-3 + α-lipoic acid (ω-3, 3 g/day contained 675 mg DHA and
975 mg EPA + α-lipoic acid, 600 mg/day in one tablet)
12 months Ø F2-isoprostane in urine Ø PC in plasma [228]
Vitamin C (1,000 mg/day) + vitamin E (400 IU/day) 12 months ↓oxidation of CSF [222]
Curcumin (1 or 4 g/day) 6 months Ø F2-isoprostane in plasma [230]
Curcuminoids (2 or 4 g/day) 24 weeks Ø F2-isoprostane in CSF [229]
Idebenone (120, 240, or 360 mg/day) 12 months nd [225]
↓ decrease, Ø no change, nd not determined, CSF cerebrospinal fluid, DHE docosahexaenoic acid, EPA eicosapentaenoic acid, ω-3 omega-3 fatty acids
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antioxidant capacity (TAC) and PC, have not been improved by
those drugs [235]. Combined therapy with memantine and
donepezil failed to improve GSH, TAC, PC, or AGEs [235].
A very recent study revealed that 6-month treatment with
memantine decreased the oxidation rate of plasma lipids in
AD patients compared with untreated patients [236]. The above
clinical trials included small sample sizes and should initiate
future examinations evaluating the effect of different types of
AD medications on OS markers in AD patients.
Animal Studies
Oxidative Biomarkers
AD can bemodeled by several procedures in animal. Injection
with scopolamine (i.p.), streptozotocin (intracerebroventricu-
lar (i.c.v.)), Aβ (i.c.v.), or apolipoprotein E (APOE) in trans-
genic models is used to study sporadic AD, while amyloid
precursor protein (APP) and presenilin 1 (PSEN1) and PSEN2
transgenic models are used to examine familial AD
[237–240]. For detailed descriptions of AD animal models,
see [241–246].
In both pharmacological and genetic models of AD, disor-
dered OS biomarkers are present in animal brains (Table 10).
MDA, HNE, or TBARS were enhanced in all of those models
in the cerebral cortex or/and hippocampus or/and the whole
brain [237–241, 247–255]. Oxidative modification of proteins
has also been demonstrated in the cortex and whole brain
homogenate of transgenic AD mice [253, 255] and in the
cerebral cortex and hippocampus of an Aβ1-42 mouse model
[247]. In addition to OS due to oxygen, there is also proof of
the presence of NS in whole brain lysates from the APP23
transgenic AD mouse model [251].
Antioxidant Defense Biomarkers
Antioxidant defense biomarkers have been found to be
changed in AD models (see Table 10). Diminished levels of
GSH in the cerebral cortex or hippocampus or in whole brain
lysates have been demonstrated in pharmacologically induced
AD animal models [237, 238, 240, 241, 247, 250, 254, 256].
Furthermore, the activities of enzymes connected with GSH
metabolism, such as GPx and GR, and the enzymes involved
in antioxidant defense (SOD and CAT) were reduced in the
hippocampus and cerebral cortex in pharmacological and ge-
netic models [237, 238, 241, 248, 249, 254–256]. It should be
noted that some studies demonstrated no change in CAT and
SOD activity in whole brain lysates in Wistar rats in the
streptozotocin model [240], while enhanced SOD, GPx, and
GR were observed in the mouse cerebral cortex and hippo-
campus following i.c.v. Aβ1-42 injection [247]. It is also im-
portant to mention that in transgenic models, the changes de-
pend on animal age. For example, APPswe/PS1dE9 mice at
2.5 months of age did not exhibit any significant changes in
measures of OS and cognitive function, whereas 3.5-month-
old mice showed diminished SOD and GPx activity and in-
creased MDA and PC levels that were accompanied by spatial
memory impairments [255].
Pharmacotherapeutic Strategy to Reduce OS
Several preclinical studies on AD have shown that many an-
tioxidants can both diminish OS and improve cognitive im-
pairments (Table 11). Among different compounds of special
interest are vitamin E, vitamin C, and α-lipoic acid. Vitamin E
given 7 days before Aβ1-42 decreased MDA and protein car-
bonyls in the mouse hippocampus and cortex [247]. Similarly,
α-lipoic acid enrichment decreased HNE levels in AbPP
Tg2576 mouse brains but did not decrease 3-NT levels
[251]. In AbPP Tg2576 mice that overexpress a mutant form
of APP (beta amyloid (βA), an (A4) precursor protein) and
show impaired learning, an R-α-lipoic acid-enriched diet, ad-
ministered for 10 months, decreased HNE levels in total brain
homogenates and also attenuated HNE protein adducts that
accumulated around amyloid deposits in the hippocampal
and cortical region, but it had little effect on cognitive perfor-
mance and brain Aβ load. This latter study seems to suggest
that a long-term antioxidant therapy that reduced oxidative
modifications provided a limited benefit [251].
In contrast to the study that used α-lipoic acid, vitamin
C, when administered to other transgenic lines, such as
APP/PSEN1 mice, did not decrease enhanced MDA levels
in the cortex or Aβ plaque deposits in the cortex and
Table 9 Clinical trials of anti-Alzheimer drugs and their influence on OS biomarkers
Anti-Alzheimer medication (dose) Duration of therapy Oxidative damage biomarker change Reference
Donepezil (10 mg/day) ≥24 months ↑GSH, Ø AGEs, TAC, PC in plasma [235]
Tivastigmine (9.5 mg/day) ≥24 months ↓AGEs, Ø GSH, TAC, PC in plasma
Donepezil (10 mg/day) + memantine (20 mg/kg) ≥24 months Ø GSH, TAC, PC, AGEs in plasma
Memantine (20 mg/day) For 6 months ↓oxidation rates of lipids in plasma [236]
↑ increase, ↓ decrease, Ø no change, AGEs advanced glycation end products, GSH glutathione, PC protein carbonyl, TAC total antioxidant capacity
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hippocampal regions in either middle-aged or aged animals
[252], although the drug administration improved memory,
according to tests that suggested that cognitive rescue was
achieved, to some degree, even in animals that suffered
from severe neuropathology. The lack of effect of vitamin
C on Aβ plaque deposits seems to result from the late
introduction of medication in this test because Aβ plaques,
considered an end point in the disease process, are detect-
able in these mice at 4–5 months, which was before the
beginning of the test [252]. It is also possible that ascorbate
had an effect on soluble Aβ [252]. Reduced vitamin C
supplementation has been shown to cause enhanced OS
in the form of MDA in APP/PSEN1 mice, which are not
able to endogenously synthesize vitamin C [257]. This lat-
ter observation led to the conclusion that vitamin C may
not be an anti-OS medication per se, but its deficiency in
AD patients may lead to oxidative damage. Interestingly,
another study showed that the long-lasting incretin hor-
mone ana logue D-Ala2GIP (g lucose -dependen t
insulinotropic polypeptide) was able to decrease OS bio-
markers (i.e., 8-OHG) and amyloid plaque load in 12- and
19-month-old APPswe/PS1 mice [258]. Many natural
compounds that possess antioxidant properties have been
tested in animal models as AD treatments. Imperatorin and
hesperidin diminished brain damage due to OS, and most
of them enhanced the power of oxidative defenses
[238–241, 259]. Moreover, meloxicam (an ant i -
inflammatory drug) and selegiline, given alone or in com-
bination, inhibited lipid peroxidation, prevented a decrease
in CAT activity, and showed memory-enhancing capacity
in a scopolamine AD model [249]. Another compound, S-
allyl cysteine, which is a sulfur-containing amino acid that
was reported to have antioxidant and neurotrophic activity,
prevented cognitive and neurobehavioral impairments,
Table 10 OS biomarkers and OS defense biomarkers in pharmacologically developed and in transgenic AD animal models
Animal model (dosage) Animal species OS biomarkers OS defense biomarkers Reference
Aβ1-42 (i.c.v. injection) Mice ↑MDA in cerebral CTX
and HIP
↓SOD, ↓GPx, ↓GSH, ↑GSSG in
cerebral CTX and HIP
[237]
Aβ1-42 injection (i.c.v. injection) Mice (Chinese Kun Ming) ↑MDA in cerebral CTX
and HIP
↓SOD, ↓GPx, ↓GSH in HIP and
cerebral CTX
[241]
Aβ1-42 (i.c.v. injection 400 pmol) Mice (C57BL/6) ↑MDA, ↑PC in cerebral
CTX and HIP
↑Mn-SOD, ↑Zn, Cu-SOD, ↑GPx
(only up to 2 days after Aβ1-42
injection), ↑GR (only 2 h after
Aβ1-42 injection) in cerebral CTX
and HIP
[247]
Scopolamine (2 mg/kg i.p. once
per day for 2 weeks)
Mice (Kun Ming) ↑MDA in HIP ↓SOD, ↓GSH in HIP [238]
Scopolamine (1 mg/kg, i.p. single
injection)
Mice (Swiss) ↑MDA in CTX and HIP ↓SOD, ↓GPx, ↓GSH-Rx in CTX
and HIP
[248]
Scopolamine (1.4 mg/kg, i.p.
single injection)
Mice (Swiss) ↑MDA in whole brain lysate ↓CAT in whole brain lysate [249]
AF64A, a cholinotoxin (2 nmol/
2 μl, bilaterally single i.c.v.
injection)
Rat (Wistar) ↑MDA in HIP nd [239]
Streptozotocin (3 mg/kg
bilaterally i.c.v. injection on
days 1 and 3)
Rat (Wistar) ↑MDA in whole brain lysate ↓GSH, Ø CAT, Ø SOD in whole
brain lysate
[240]
Streptozotocin (2.57 mg/kg
bilaterally single i.c.v. injection)
Mice (Swiss albino) ↑TBARS in HIP ↓GSH, ↓GPx, ↓GR in HIP [250]
Streptozotocin (3.0 mg/kg i.c.v.
single injection, 5 μl/injection
per site)
Rat (Wistar) ↑HNE, ↑MDA, ↑TBARS,
↑PC in HIP
↓GSH, ↓GPx, ↓GR, ↓CAT, ↓SOD
in HIP
[256]
AbPP Tg2576 transgenic mice ↑HNE, ↑3-NT in whole brain nd [251]
APP/PSEN1 transgenic mice ↑MDA in HIP nd [252]
APP23 transgenic mice ↑PC in CTX nd [253]
Heterozygote APP transgenic mice ↑TBARS in the brain
homogenate
↓GSH, ↓SOD in the brain homogenate [254]
APPswe/PS1dE9 transgenic mice ↑MDA, ↑PC in the brain
homogenate
↓SOD, ↓GPx in the brain homogenate [255]
↑ increase, ↓ decrease, nd not determined, 3-NT 3-nitrotyrosine,CTX cortex,GSH glutathione,CATcatalase,GPx glutathione peroxidase,GR glutathione
reductase, GSSG oxidized glutathione, HIP hippocampus, HNE 4-hydroxynonenal, i.c.v. intracerebroventricular, i.p. intraperitoneal, MDA
malonyldialdehyde, Mn-SOD manganese superoxide dismutase (located in mitochondria), PC protein carbonyl, SOD superoxide dismutase, TBARS
thiobarbituric acid reactive substances, Zn, Cu-SOD copper/zinc superoxide dismutase (located in cytoplasm)
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prevented ROS damage in the hippocampus, and augment-
ed endogenous antioxidant enzymes in a streptozocin AD
model [250]. Similar results were obtained when melatonin
was given chronically to a genetic AD mouse model, as the
drug alleviated OS and enhanced GSH levels [254, 260].
Moreover, results from Feng et al. [254] showed that OS is
an early event in AD pathogenesis and that antioxidant
therapies may be beneficial if given at this stage of the
disease [254].
As shown above, results from animal ADmodels that have
used various pharmacological compounds to reduce OS and to
alleviate memory deficits in AD are promising but do not yet
parallel the results obtained in clinical trials.
Anti-Alzheimer’s Disease Drugs that Modulate Oxidative
Balance
Medications used to treat Alzheimer’s disease have been
shown to have antioxidant properties that depend on the dose
and AD model (Table 12). For example, tacrine, the first an-
ticholinesterase inhibitor approved by the Food and Drug Ad-
ministration (FDA), was shown to suppress OS in an animal
AD model [261]. In fact, tacrine (50–800 μg/kg i.m.) in-
creased the FRAP value, which serves as a measure of
Bantioxidant power^ [262], without elevating any marker of
OS-associated damage in brain tissue. The effect of tacrine
may therefore be considered to be positive when this drug is
Table 11 Studies with substances/drugs with antioxidant properties in different AD animal models and their influence on oxidative damage and anti-
oxidative defense and biomarkers
Model Oxidative damage and
defense biomarkers
Drug and route of administration Changes in oxidative
defense biomarkers
Reference
Aβ1–42 i.c.v. to mice
(Chinese Kun Ming)
↑MDA, ↓SOD, ↓GPx,
↓GSH in HIP and
cerebral CTX
Schisantherin A 0.1 mg/kg for 5 days
i.c.v., injection started after 3 days
from Aβ1–42 injection
↓MDA in cerebral CTX,
↑SOD, ↑GPx, ↑GSH
in HIP and cerebral CTX
[241]
Aβ1–42 i.c.v. to mice
(C57BL/6)
↑MDA, ↑PC, ↑Mn-SOD,
↑Zn, Cu-SOD, ↑GPx,
↑GR in cerebral CTX
and HIP
Vitamin E 150 mg/kg, p.o. for 27 days,
administration began 7 days before
Aβ1–42 i.c.v.
↓MDA, ↓PC, ↓Mn-SOD,
↓Zn, Cu-SOD, ↑GPx,
Ø GR in cerebral CTX
and HIP
[247]
AF64A (a cholinotoxin)
2 nmol/2 μl, bilaterally
i.c.v. to rats (Wistar)
↑MDA in HIP Piperine 5 or 10 mg/kg p.o. 2 weeks
before and 1 week after AF64A
↓MDA in HIP [239]
Streptozotocin 2.57 mg/
kg i.c.v. to mice
(Swiss albino)
↑TBARS, ↓GSH, ↓GPx,
↓GR in HIP
S-allyl cysteine 30 mg/kg i.p. for 15 days
pre-treatment before streptozocin
↓TBARS, ↑GSH, ↑GPx,
↑GR in HIP
[250]
Scopolamine 1 mg/kg i.p
single injection to mice
(Swiss) 20 min before
pretest (memory acquisition)
or 15 min after pretest
(memory consolidation)
↑MDA, ↓SOD, ↓GPx, ↓
GR in CTX and HIP
Imperatorin 1, 5, or 10 mg/kg i.p. 2×/day
for 7 days (on 7th day (pretest):10 min
before scopolamine injection or 15 min
after scopolamine injection
↓MDA, ↑SOD in CTX and
HIP, ↑GPx in CTX and
HIP, ↑GR in CTX
[248]
Mice (AbPP Tg2576) ↑HNE, ↑3-NT in brain
homogenates
α-lipoic acid 30 mg/kg/day enriched diet
for 10 months
↓HNE, Ø 3-NT in brain
homogenates
[251]
Mice (APP/PSEN1 transgenic) ↑MDA in HIP Vitamin C 125 mg/kg i.p. for 12 days Ø MDA in HIP [252]
Mice (Gulo−/− APP/PSEN1) MDA level in CTX on
vitamin C content
standard diet (0.33 g/L
of drinking water) not
changed
Vitamin C- low diet content 0.099 g/L
of drinking water
↑MDA in CTX [257]
Mice (APPswe/PS1) nd Melatonin 5 mg/kg p.o. for 5.5 months ↓MDA, ↓PC in HIP [260]
Mice (heterozygote APP) ↑TBARS, ↓GSH, ↓SOD
in the brain homogenate
Melatonin 10 mg/kg/day for 4 months
intargastrically
↓TBARS, ↑GSH, ↑SOD in
the brain homogenate
[254]
Mice (APPswe/PS1) nd Long-lasting incretin hormone analogue
D-Ala2GIP
35 days at 25 nmol/kg i.p. once daily
↓8-OHG in CA1 HIP region
(in 12 and 19 months old
mice)
[258]
Mice (APPswe/PS1) ↑H2O2, ↑MDA, ↓GSH, ↓
TAC in whole brain
lysate
Hesperidin 100 mg/kg per day for
16 weeks in chow
↓H2O2, ↓MDA, ↑GSH, ↑TAC
in whole brain lysate
[259]
↑ increase, ↓ decrease, Ø no changes, 3-NT 3-nitrotyrosine, CAT catalase, CTX cortex, D-Ala2GIP glucose-dependent insulinotropic polypeptide, GPx
glutathione peroxidase, GR glutathione reductase, GSH glutathione, GSSG oxidized glutathione, HIP hippocampus, HNE 4-hydroxynonenal, i.c.v.
intracerebroventricular, i.p. intraperitoneal,MDAmalonyldialdehyde,Mn-SODmanganese superoxide dismutase (located in mitochondria), PC protein
carbonyl, SOD superoxide dismutase, TAC total antioxidant capacity, TBARS thiobarbituric acid reactive substances, Zn, Cu-SOD copper/zinc super-
oxide dismutase (located in cytoplasm)
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used in doses that stimulate the antioxidant system without
inducing oxidative damage in brain tissue [263].
Donepezil is another cholinesterase inhibitor used in AD
patients that, when given in doses as low as 3 mg/kg [259],
5 mg/kg [238, 249], or even 0.01 mg/kg [241] in a mouse AD
model, both increased antioxidant power (CAT, SOD, GSH,
or GPx, depending on the dose; see Table 12) and diminished
lipid peroxidation [238, 241, 249]. However, donepezil, when
given in a similar dose of 2.5 mg/kg, failed to combat OS
biomarkers and to stimulate antioxidant defenses in the
APPswe/PS1 transgenic mouse AD model [259]. Those con-
tradictory results come from studies using non-transgenic and
transgenic animal AD models, which means that the multiple
adaptations developed for use in these transgenic animals
could be the reason for the observed difference in outcomes.
Another medication used in AD treatment is rivastigmine.
This drug neither attenuated lipid peroxidation nor restored
GSH depletion in the brains of rats in an AD model [264],
although an older study indicated antioxidant properties for
rivastigmine when ADwas induced in rats by aluminum chlo-
ride administration [265]. Such differences in the effects of
rivastigmine might be caused either by differences in the AD
model used in the study (aluminum chlorate p.o. vs. colchicine
i.c.v. models) or by differences in the rivastigmine dose regi-
men (0.3 mg/kg for 3 months vs. 2.5 mg/kg p.o. for 28 days).
Based on the above scant reports, it is too soon to either con-
firm or exclude rivastigmine as an effective OS scavenger in
AD.
A single report showed the ability of another AChE inhib-
itor, galantamine, to reduce OS. In a cognitive impairment
Table 12 Trials with anti-Alzheimer drugs in different AD animal models and their influence on oxidative damage and anti-oxidative defense
biomarkers
Model Oxidative defense biomarkers Drug and route of administration Changes in oxidative
defense biomarkers
Reference
Scopolamine 2 mg/kg i.p. once
per day for 2 weeks to mice
(Kun Ming)
↑MDA, ↓SOD, ↓GSH in HIP Donepezil (3 mg/kg/day p.o.
once per day for 2 weeks)
↓MDA, ↓SOD, ↑GSH in
HIP
[238]
Aβ1–42 3 μl of 1 mg/ml solution.
i.c.v. to mice (Chinese Kun
Ming)
↑MDA, ↓SOD, ↓GPx, ↓GSH
in HIP and cerebral CTX
Donepezil (0.01 mg/kg/day i.c.v.
for 14 days)
↓MDA, ↑GSH, ↑GPx, Ø
SOD in HIP and
cerebral CTX
[241]
Mice APPswe/PS1 (transgenic
model)
↑H2O2, ↑MDA, ↓GSH, ↓TAC Donepezil (2.5 mg/kg/day for
16 weeks)
↓H2O2, ↓MDA, ↓GSH, Ø
TAC
[259]
Scopolamine 1.4 mg/kg i.p. once
a day for 9 days to mice
(Swiss)
↑MDA, ↓CAT in whole brain
lysate
Donepezil (5 mg/kg p.o. once a
day for 9 days before
scopolamine administration)
↓MDA, ↑CAT in whole
brain lysate
[249]
Streptozotocin 0.5 mg/kg i.c. on
1st and 3rd day to mice (Swiss
albino)
↑MDA, ↓GSH in whole brain
lysate
Tacrine (5 mg/kg/day p.o.) or
donepezil (5 mg/kg/day p.o.)
for 7 days
↓MDA, ↑GSH (not
significant) in whole
brain lysate
[261]
Colchicine 5 μg/5 μl i.c.v. injec-
tion to rats (Wistar)
↑MDA, ↓GSH in brain Rivastigmine (2.5 mg/kg p.o. for
28 days started 7 days before
colchicine injection)
Ø MDA, Ø GSH in brain [264]
Kainic acid (KA) 0.4 μg/2 μl
single unilateral
intrahippocampal injection to
rats (Wistar)
↑MDA, ↑nitrate, ↓GSH, ↑
GSSG in HIP
Galantamine (2.5 mg or 5 mg/kg
for 14 days starting from the
day of KA injection)
↑MDA, ↑nitrate, ↓GSH, ↑
GSSG in HIP
[266]
Αβ25–35 i.c.v. injection once a
day for 3 consecutive days to
rats (Wistar)
↑iNOS in HIP Memantine (5 mg/kg/day i.p. for
8 days, 3 times after Αβ25–35
injection and for 5 following
post-Αβ25–35 days)
↓i NOS in HIP [268]
Age-induced memory
impairment in rats (Wistar)
(24 months old)
↑PC in HIP and CTX Memantine (20 mg/kg i.p. for
21 days)
↓PC in HIP and CTX [267]
Streptozocin 10 μl injection of
3 mg/kg bilaterally on 1st and
3rd day to rats (Sprague-
Dawley)
↑ROS, ↑nitrate in CTX and
HIP
Memantine (10 mg/kg p.o. for
13 days starting from STZ
injection)
↓ROS, ↓nitrate in CTX
and HIP
[269]
Kainic acid 200 ng/10 μl bilater-
ally i.c.v. to rats (Sprague-
Dawley)
↑ROS, ↑MDA, in STR, CTX,
cerebellum, HIP, ↑nitrite in
CTX, HIP
Memantine (10 mg/kg p.o. for
13 days starting from the day
of OKA injection)
↓ROS, ↓MDA in STR,
CTX, cerebellum, HIP,
↓nitrite in CTX, HIP
[270]
↑ increase, ↓ decrease, Ø no changes, nd not determined, 3-NT 3-nitrotyrosine, AlCl3 aluminum chloride, CAT catalase, CTX cortex, GPx glutathione
peroxidase,GR glutathione reductase,GSH glutathione,GSSG oxidized glutathione,HIP hippocampus,HNE 4-hydroxynonenal, i.c. intracerebral, i.c.v.
intracerebroventricular, i.p. intraperitoneal, KA kainic acid, MDA malonyldialdehyde, PC protein carbonyl, SOD superoxide dismutase, STR striatum,
TAC total antioxidant capacity, TBARS thiobarbituric acid reactive substances
Mol Neurobiol (2016) 53:4094–4125 4115
animal model, galantamine decreased lipid peroxidation, ni-
trate, and GSSG levels, enhanced SOD activity, and impaired
GSH levels following kainic acid intrahippocampal injection,
and it restored cognitive deficits as well [266].
Memantine has also been widely studied in preclinical AD
models. For example, it was shown that memantine reduced
oxidative damage to proteins in the cortex and hippocampus
but not in the striatum, resulting in the reversal of concomitant
age-induced recognition memory deficits in aged rats [267].
Other studies found that memantine diminished the level of
inducible forms of NOS in an Αβ25–35 AD model [268] and
ROS and nitrate levels in the hippocampus and cortex in a
streptozotocin AD model [269] and in a kainic acid-induced
model of dementia [270]. However, memantine was shown to
have neuroprotective properties not only in AD models but
also in 3-nitropropionic acid [271], rotenone [272], and
diisopropylphosphorofluoridate (DFP) toxicity models [273].
There is a wide range of evidence showing that several
drugs used to treat AD have antioxidant properties, suggesting
that at least part of their efficacy in animal models may come
from that action.
Summary and Conclusions
In general, the presence of OS in the pathophysiology of many
neurodegenerative disorders, including ALS, PD, and AD, is a
well-recognized phenomenon. The results of many in vitro
and in vivo preclinical and clinical studies have consistently
demonstrated that OS is one of the crucial players in the de-
generation that occurs in the nervous system. The imbalance
between OS and antioxidant defense systems seems to be a
universal condition in neurodegeneration. However, what can
be surprising is that the results of many studies often provide
different results when trying to determine the exact mecha-
nisms that underlie OS and to determine which of the markers
of OS could be clinically useful. What has been shown to be
elevated in one study does not necessarily have to rise in
another. In preclinical studies, these divergent results could
be explained by the use of different models, different species,
or different methodologies. As for the clinical setting, it must
be stressed that the number of patients available for study is
usually small because they are in different stages of their dis-
eases, there are often coexisting comorbidities, and, last but
not least, they often take many other medications with differ-
ent pro- or antioxidant properties. The analysis of potential
biomarkers under these conditions is extremely difficult.
Therefore, assessing the real efficacy of potential antioxidant
drugs is a challenge. However, there are some data, if even
modest, that some of the existing drugs possess anti-oxidant
properties and that they could slow down neurodegenerative
processes and improve our understanding of the significance
of OS in the pathobiology of these untreatable conditions.
The results of clinical and preclinical studies have demon-
strated the presence of elevated levels of OS biomarkers as
well as impairments to antioxidant defenses in the brain and
peripheral tissues in PD, AD, and ALS. As the currently avail-
able therapies for these neurodegenerative diseases are not
sufficiently effective for treating disease symptoms, novel
substances are searched for. Among these, drugs with antiox-
idant activity, which are widely studied as a possible anti-
neurodegenerative PD, AD, or ALS agents, can efficiently
normalize biomarkers of the oxidant/antioxidant balance in
animal models. Most such drugs have so far failed to slow
down the progression of the disease or to prolong the lives
of pat ients . Some except ions within these ant i -
neurodegenerative drugs exist, and they give hope and inspire
further research.
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